hsa-miR-206 muscular dystrophies miR-206: miR-206 high expression for muscle regeneration and maturation 18827405 HMDD v2.0 hsa-miR-182-5p ovarian cancer up 24512620 dbDEMC v2.0 hsa-miR-938 colorectal cancer up 21844009 dbDEMC v2.0 hsa-miR-451a myocardial infarction dysregulation 20075508 HMDD v2.0 hsa-miR-206 myocardial infarction miR-206: Upregulated expression in a rat model 19245789 HMDD v2.0 hsa-miR-107 hepatocellular carcinoma recurence related 21298008 HMDD v2.0 hsa-miR-588 ovarian cancer up 22235027 dbDEMC v2.0 hsa-miR-17-5p pancreatic cancer promote cell growth|promote cell invasion 20703102 OncomiRDB hsa-miR-582-3p bladder carcinoma reduce cell proliferation|reduce cell invasion|reduce tumor growth|reduce metastasis 23295946 OncomiRDB hsa-miR-765 rectal cancer Microarray analysis selected 14 miRNAs as being differentially expressed in TRG1 patients, and 13 were confirmed by qRT-PCR: 11 miRNAs (miR-1183, miR-483-5p, miR-622, miR-125a-3p, miR-1224-5p, miR-188-5p, miR-1471, miR-671-5p, miR-1909?, miR-630, miR-765) were significantly upregulated in TRG1 patients, 2 (miR-1274b, miR-720) were downexpressed. MiR-622 and miR-630 had a 100% sensitivity and specificity in selecting TRG1 cases. 22172905 HMDD v2.0 hsa-miR-199a-3p hepatocellular carcinoma reduce cell proliferation|reduce cell invasion 21055388 OncomiRDB hsa-miR-107 chronic lymphocytic leukemia NPA 19692702 OncomiRDB hsa-miR-107 non small cell lung cancer inhibit cell growth|induce cell cycle G1 arrest 19688090 OncomiRDB hsa-miR-223-5p colon cancer up 24239208 dbDEMC v2.0 hsa-miR-1290 hpv infection We found hypermethylation of miR-432, miR-1286, miR-641, miR-1290, miR-1287 and miR-95 may have some relationship with HPV infection in cervical cell lines. 23732000 HMDD v2.0 hsa-miR-429 ovarian cancer up 21811625 dbDEMC v2.0 hsa-miR-320a gastric cancer A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemoresistance 22112324 HMDD v2.0 hsa-miR-520b breast cancer MicroRNA-520/373 family functions as a tumor suppressor in estrogen receptor negative breast cancer by targeting NF-kB and TGF-beta signaling pathways. 22158050 HMDD v2.0 hsa-miR-375 thyroid carcinoma up 27036030 dbDEMC v2.0 hsa-miR-199b-5p pancreatic cancer down 21953293 dbDEMC v2.0 hsa-miR-137 leiomyoma deregulated 22446413 HMDD v2.0 hsa-miR-520b breast cancer inhibit cell migration 21343296 OncomiRDB hsa-miR-206 chronic obstructive pulmonary disease A reduction in expression of miR-1 (2.5-fold, p=0.01) and the myocardin-related transcription factors (MRTFs) A and B was observed in patients compared with controls (MRTF-A mRNA: twofold, p=0.028; MRTF-B mRNA: fourfold, p=0.011). miR-1 expression was associated with smoking history, lung function, fat-free mass index, 6 min walk distance and percentage of type 1 fibres. miR-133 and miR-206 were negatively correlated with daily physical activity. Insulin-like growth factor 1 mRNA was increased in the patients and miR-1 was negatively correlated with phosphorylation of the kinase Akt. Furthermore, the protein levels of histone deacetylase 4, another miR-1 target, were increased in the patients. 21998125 HMDD v2.0 hsa-miR-378f renal cell carcinoma The level of miR-378 was significantly increased in serum of ccRCC patients. 22542158 HMDD v2.0 hsa-miR-635 adenoviridae infections miR-635:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control 20634878 HMDD v2.0 hsa-miR-133b gastric cancer miR-133b: down-regulated 19175831 HMDD v2.0 hsa-miR-146b-5p triple negative sporadic breast cancer increase cell proliferation|reduce homologous recombination rate 21472990 OncomiRDB hsa-miR-524-5p glioma inhibit cell proliferation|inhibit cell invasion 22871495 OncomiRDB hsa-miR-429 systemic lupus erythematosus The serum levels of miR-200a, miR-200b, miR-200c, miR-429, miR-205 and miR-192, and urinary miR-200a, miR-200c, miR-141, miR-429 and miR-192 of SLE patients were lower than those of controls. 21372198 HMDD v2.0 hsa-miR-484 adrenocortical adenoma miR-484:16 microRNAs were down-regulated, including miR-200b and miR-203, whereas 21 microRNAs were up-regulated, miR-210 and miR-484 among them 19849700 HMDD v2.0 hsa-miR-28-5p cervical cancer up 22330141 dbDEMC v2.0 hsa-miR-375 squamous cervical cancer inhibit cell proliferation|block cell cycle G1/S transition|inhibit cell migration|inhibit cell invasion 21945323 OncomiRDB hsa-miR-326 glioma induce cytotoxicity|reduce tumorigenicity 19955368 OncomiRDB hsa-miR-1275 glioma stem-like cell increase cell growth 22736761 OncomiRDB hsa-miR-378c bladder carcinoma miR-10b, 19a, 126, 145, 221, 296-5p and 378 were significantly down-regulated in bladder carcinoma compared to adjacent normal urothelium. 22704449 HMDD v2.0 hsa-miR-107 colorectal cancer miR-103/107 Promote Metastasis of Colorectal Cancer by Targeting the Metastasis Suppressors DAPK and KLF4. 22593189 HMDD v2.0 hsa-miR-143-5p colon cancer down 24239208 dbDEMC v2.0 hsa-miR-421 squamous cell carcinoma Aberrant overexpression of miR-421 downregulates ATM and leads to a pronounced DSB repair defect and clinical hypersensitivity in SKX squamous cell carcinoma 23199656 HMDD v2.0 hsa-miR-137 astrocytoma miR-137:The down-regulation of hsa-miR-137 in astrocytomas was shown to be associated with advanced clinical stages of this disease 20219352 HMDD v2.0 hsa-miR-378g bladder carcinoma miR-10b, 19a, 126, 145, 221, 296-5p and 378 were significantly down-regulated in bladder carcinoma compared to adjacent normal urothelium. 22704449 HMDD v2.0 hsa-miR-137 oral cancer MicroRNA-137 promoter methylation in oral lichen planus and oral squamous cell carcinoma 23121285 HMDD v2.0 hsa-miR-142-5p colon cancer up 24239208 dbDEMC v2.0 hsa-miR-184 waldenstrom macroglobulinemia miR-184: increased expression 19074725 HMDD v2.0 hsa-miR-28-5p colorectal cancer reduce cell proliferation|reduce cell migration|reduce cell invasion 22240480 OncomiRDB hsa-miR-378h renal cell carcinoma The level of miR-378 was significantly increased in serum of ccRCC patients. 22542158 HMDD v2.0 hsa-miR-206 schizophrenia SNP (rs17578796) disease susceptibility 17849003 HMDD v2.0 hsa-miR-451a glioblastoma miR-451: MIR-451 and Imatinib mesylate inhibit tumor growth of Glioblastoma stem cells 18765229 HMDD v2.0 hsa-miR-566 adenoviridae infections miR-566:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control 20634878 HMDD v2.0 hsa-miR-199a-3p melanoma promote metastatic invasion|promote angiogenesis|promote colonization 23142051 OncomiRDB hsa-miR-378h basal cell carcinoma downregulated in the tumor center 22540308 HMDD v2.0 hsa-miR-3148 systemic lupus erythematosus MicroRNA-3148 Modulates Allelic Expression of Toll-Like Receptor 7 Variant Associated with Systemic Lupus Erythematosus 23468661 HMDD v2.0 hsa-miR-658 gastric cancer A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemoresistance 22112324 HMDD v2.0 hsa-miR-542-5p neuroblastoma decrease cell invasion|inhibit tumor growth|inhibit metastasis 21310526 OncomiRDB hsa-miR-448 breast cancer inhibit epithelial-mesenchymal transition 20798686 OncomiRDB hsa-miR-34a-5p colon cancer down 24239208 dbDEMC v2.0 hsa-miR-612 lupus vulgaris miR-612: upregulation 18998140 HMDD v2.0 hsa-miR-184 glioma inhibit cell viability|inhibit cell proliferation|induce apoptosis|inhibit cell invasion 19775293 OncomiRDB hsa-miR-483-5p glioma inhibit cell proliferation|induce cell cycle G0/G1 arrest 22465663 OncomiRDB hsa-miR-200a-3p colon cancer up 24239208 dbDEMC v2.0 hsa-miR-28-3p colorectal cancer increase cell migration|increase cell invasion|promote metastasis 22240480 OncomiRDB hsa-miR-512-3p hepatocellular carcinoma promote taxol-induced apoptosis 20372864 OncomiRDB hsa-miR-516a-3p sporadic pituitary adenoma inhibit cell proliferation 20668041 OncomiRDB hsa-miR-198 coronary artery disease a cluster of three microRNAs including miR-134, miR-198, and miR-370, suggesting that the microRNA signatures can be used to identify patients at risk for acute coronary syndromes 20230787 HMDD v2.0 hsa-miR-760 renal cell carcinoma Up-regulated in the blook serum of patients with renal cell carcinoma compared to healthy controls. 22440013 HMDD v2.0 hsa-miR-298 breast cancer reduce doxorubicin resistance 22521303 OncomiRDB hsa-miR-206 gastric cancer A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemoresistance 22112324 HMDD v2.0 hsa-miR-429 liver cancer down 24169343 dbDEMC v2.0 hsa-miR-520b cancer miR-520b: miR-520b was induced by IFN-gamma, leading to a reduction in MICA surface protein levels 19109132 HMDD v2.0 hsa-miR-151b non small cell lung cancer High expression of miR-100 and low expression of miRNA-93, miRNA-134, miRNA-151 and miRNA-345 were associated with poor survival in both the training and validation cohort. 22937028 HMDD v2.0 hsa-miR-378c bladder carcinoma hsa-miR-29c, hsa-miR-200a, hsa-miR-378, hsa-miR-429, hsa-miR-200c and hsa-miR-141 were up-regulated, while hsa-miR-451 was down-regulated. 22886973 HMDD v2.0 hsa-miR-375 prostate cancer NPA 21593139 OncomiRDB hsa-miR-320d breast cancer Expression of the Pten-miR-320-Ets2-regulated secretome distinguished human normal breast stroma from tumour stroma and robustly correlated with recurrence in breast cancer patients. This work reveals miR-320 as a critical component of the Pten tumour-suppressor axis that acts in stromal fibroblasts to reprogramme the tumour microenvironment and curtail tumour progression. 22179046 HMDD v2.0 hsa-miR-206 breast cancer miR-206 may suppress invasion and migration of MDA-MB-231 cells in vitro partly via regulating actin cytoskeleton remodelling such as filopodia formation 21302623 HMDD v2.0 hsa-miR-590-5p hepatocellular carcinoma promote proliferation|promote invasion 22684895 OncomiRDB hsa-miR-137 Alzheimer's disease Blood serum expressio level of these miRNAs may be non-invasive biomarkers for Alzheimer's disease. 22155483 HMDD v2.0 hsa-miR-206 lung cancer serum;Alteration of serum miR-206 and miR-133b is associated with lung carcinogenesis induced by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone 23337359 HMDD v2.0 hsa-miR-375 oesophageal squamous cell carcinoma inhibit clonogenicity|inhibit cell motility|inhibit cell proliferation|reduce tumour formation|reduce metastasis 21813472 OncomiRDB hsa-miR-199b-5p acute myeloid leukemia inhibit in collagen IV induced migration 22374871 OncomiRDB hsa-miR-502-3p kidney cancer down 23799849 dbDEMC v2.0 hsa-miR-199b-5p hepatocellular carcinoma inhibit cell growth|enhance radiosensitivity 21557766 OncomiRDB hsa-miR-449a adrenocortical carcinoma miR-449: upregulated 19351815 HMDD v2.0 hsa-miR-300 bladder carcinoma In grade I, grade II, grade III, grade I + II + III, infiltrating and non-infiltrating groups, hsa-miR-29b-1* was up-regulated while hsa-miR-923 and hsa-miR-300 were down-regulated 21223810 HMDD v2.0 hsa-miR-302f cancer overexpressed 20332240 HMDD v2.0 hsa-miR-137 rectal cancer miR-137: frequently upregulated in response to capecitabine chemoradiotherapy of rectal cancer 18695884 HMDD v2.0 hsa-miR-451a breast cancer miR-451: Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin 18645025 HMDD v2.0 hsa-miR-325 heart failure downregulated 17606841 HMDD v2.0 hsa-miR-107 crohn disease The miRNA showed significantly higher levels in the blood from patients with CD compared with the healthy controls. 22386737 HMDD v2.0 hsa-miR-137 melanoma NPA 18316599 OncomiRDB hsa-miR-421 gastric cancer Gastric juice microRNA-421 is a new biomarker for screening gastric cancer. 22926798 HMDD v2.0 hsa-miR-7-5p melanoma inhibit cell migration|inhibit cell invasion 23206698 OncomiRDB hsa-miR-107 NPA promote cell migration|promote metastatis|induce epithelial-mesenchymal transition 20603000 OncomiRDB hsa-miR-449a non small cell lung cancer miR-449a/b was significantly down-regulated in lung cancer tissues compared with normal lung tissues, while HDAC1 was up-regulated in lung cancer tissues.Combined treatment with miR-449a and HDAC inhibitors (apicidin and TSA) in HCC95 cells showed a significant growth reduction compared to mono-treatment with HDAC inhibitors. Interestingly, combination treatment with TSA and miR-449a was had significant growth reduction than a combination with apicidin. 22078727 HMDD v2.0 hsa-miR-520e gout There was a clear link between the rs1333049 genotypic and allelic frequencies between gout cases and controls. There was a significantly increased risk of gout in carriers of the CC genotype.This SNP is homologous to miR-519 and miR-520. 21558165 HMDD v2.0 hsa-miR-583 hepatitis b Circulating miR-583 and miR-663 Refer to ZHENG Differentiation in Chronic Hepatitis B 23554832 HMDD v2.0 hsa-miR-147a hepatocellular carcinoma recurrence-related in hepatocellular carcinoma 22552153 HMDD v2.0 hsa-miR-375 squamous cell carcinoma MicroRNA-375 inhibits tumour growth and metastasis in oesophageal squamous cell carcinoma through repressing insulin-like growth factor 1 receptor. 21813472 HMDD v2.0 hsa-miR-137 colorectal cancer miR-215, miR-137, miR-708, miR-31,and miR-135b were differentially expressed in APC tumors and miR-215, miR-133a,miR-467d, miR-218, miR-708, miR-31, and miR-135b in colitis-associated tumors. 21532750 HMDD v2.0 hsa-miR-378i bladder carcinoma miR-10b, 19a, 126, 145, 221, 296-5p and 378 were significantly down-regulated in bladder carcinoma compared to adjacent normal urothelium. 22704449 HMDD v2.0 hsa-miR-129-5p thyroid carcinoma induce cell death|increase drug sensivitiy 21946411 OncomiRDB hsa-miR-451a non small cell lung cancer Plasma miR-21, miR-30d, miR-451, miR-10a, miR-30e-5p and miR-126*, miR-126, miR-145) were differentially expressed 23756108 HMDD v2.0 hsa-miR-137 adrenocortical carcinoma miR-137: upregulated 19351815 HMDD v2.0 hsa-miR-451b bcr-abl positive chronic myelogenous leukemia Myc induced miR-144/451 contributes to the acquired imatinib resistance in chronic myelogenous leukemia cell K562. 22842456 HMDD v2.0 hsa-miR-520h lung cancer MiR-520h-mediated FOXC2 regulation is critical for inhibition of lung cancer progression by resveratrol. 22410781 HMDD v2.0 hsa-miR-199a-5p adrenocortical carcinoma down 20484036 dbDEMC v2.0 hsa-miR-137 brain cancer up 18973228 dbDEMC v2.0 hsa-miR-17-5p pancreatic cancer increase cell growth|inhibit apoptosis|decrease chemosensitivity to gemcitabine 23001407 OncomiRDB hsa-miR-484 autistic disorder miR-484: deregulation 18563458 HMDD v2.0 hsa-miR-107 bladder carcinoma Specific deletion of p53 in urothelial cells is associated with specific overexpression of miR-18a and miR-19a and down-regulation of miR-107. 21388952 HMDD v2.0 hsa-miR-449a gastric cancer miR-449 inhibits cell proliferation and is down-regulated in gastric cancer. 21418558 HMDD v2.0 hsa-miR-1471 rectal cancer Microarray analysis selected 14 miRNAs as being differentially expressed in TRG1 patients, and 13 were confirmed by qRT-PCR: 11 miRNAs (miR-1183, miR-483-5p, miR-622, miR-125a-3p, miR-1224-5p, miR-188-5p, miR-1471, miR-671-5p, miR-1909?, miR-630, miR-765) were significantly upregulated in TRG1 patients, 2 (miR-1274b, miR-720) were downexpressed. MiR-622 and miR-630 had a 100% sensitivity and specificity in selecting TRG1 cases. 22172905 HMDD v2.0 hsa-miR-1254 non small cell lung cancer miR-1254 and miR-574-5p: Serum-Based microRNA Biomarkers for Early-Stage non small cell lung cancer. The expression of hsa-miR-1254 and hsa-miR-574-5p was significantly increased in the early-stage NSCLC samples with respect to the controls. The utility of miR-1254 and miR-574-5p serum-based biomarkers as minimally invasive screening and triage tools for subsequent diagnostic evaluation warrants additional validation. 21258252 HMDD v2.0 hsa-miR-509-3p leukemia up 25368993 dbDEMC v2.0 hsa-miR-4306 breast cancer The miRNA is up-regulated in whole blood of breast cancer patients 22242178 HMDD v2.0 hsa-miR-451a polycythemia vera upregulation 17976518 HMDD v2.0 hsa-miR-27a-3p colon cancer up 24239208 dbDEMC v2.0 hsa-miR-4787-5p colon cancer down 24239208 dbDEMC v2.0 hsa-miR-429 heart failure upregulated 17606841 HMDD v2.0 hsa-miR-483-5p kidney cancer up 24298054 dbDEMC v2.0 hsa-miR-492 colorectal cancer differentially expressed 22850566 HMDD v2.0 hsa-miR-569 systemic lupus erythematosus rs1057233 alters a target sequence for microRNA hsa-miR-569 (miR-569). 21360505 HMDD v2.0 hsa-miR-513a-5p ovarian cancer up 24512620 dbDEMC v2.0 hsa-miR-146b-5p glioma decrease cell invasion|decrease cell migration 20874002 OncomiRDB hsa-miR-302e cancer overexpressed 20332240 HMDD v2.0 hsa-miR-596 oral squamous cell carcinoma reduce cell growth|induce apoptosis 23233740 OncomiRDB hsa-miR-125a-5p hepatocellular carcinoma induce cell cycle G phase arrest 23079745 OncomiRDB hsa-miR-451a gastric cancer Three miRs, miR-451, miR-199a-3p and miR-195 were found to be differentially expressed in tumors from patients with good prognosis vs patients with bad prognosis (P < 0.0002, 0.0027 and 0.0046 respectively). High expression of each miR was associated with poorer prognosis for both recurrence and survival. Using miR-451, the positive predictive value for non-recurrence was 100% (13/13). 22046085 HMDD v2.0 hsa-miR-320a hepatocellular carcinoma This miRNA was down-regulated in HepG2 cells treated with BJA32515. 22027761 HMDD v2.0 hsa-miR-520e hepatocellular carcinoma hsa-miR-520e was down-regulated in HepG2 cells after 5 hours of culture with epigallocatechin gallate. 21998738 HMDD v2.0 hsa-miR-375 squamous cell carcinoma the plasma level of miR-21 was significantly higher (P=0.0218) and that of miR-375 (P=0.0052) was significantly lower in ESCC patients than controls. (2) The high plasma miR-21 levels reflected tumour levels in all cases (100%). The plasma level of miR-21 was significantly reduced in postoperative samples (P=0.0058). (3) On validation analysis, the plasma level of miR-21 tended to be higher in ESCC patients (P=0.0649), while that of miR-375 was significantly lower (P<0.0001) and the miR-21/miR-375 ratio was significantly higher (P<0.0001) in ESCC patients than in controls. The value of the area under the receiver-operating characteristic curve (AUC) was 0.816 for the miR-21/miR-375 ratio assay. Patients with a high plasma level of miR-21 tended to have greater vascular invasion (P=0.1554) and to show a high correlation with recurrence (P=0.0164). 21673684 HMDD v2.0 hsa-miR-451a breast cancer Tamoxifen downregulation of miR-451 increases 14-3-3 and promotes breast cancer cell survival and endocrine resistance. 21666713 HMDD v2.0 hsa-miR-520e hepatocellular carcinoma suppress cell proliferation 22105365 OncomiRDB hsa-miR-429 pancreatic cancer Differentially expressed miRNAs including miR-99a, miR-100, miR-125b, miR-192, and miR-429 were detected in pancreatic cancer stem cells. 21785383 HMDD v2.0 hsa-miR-507 melanoma miR-506-514 cluster was consistently overexpressed in nearly all melanomas tested (30-60 fold, P<0.001), regardless of mutations in N-ras or B-raf. 21860416 HMDD v2.0 hsa-miR-663a bcr-abl positive chronic myelogenous leukemia The CpG islands in the upstream regions of miR-663, miR-369, miR-615, and miR-410, and promoter activity was detected in the upstream region of pre-miR-663. We found that a decrease in methylation of a CpG island could up-regulate the expression of miR-663, suggesting that miR-663 could be regulated by DNA methylation. 22089542 HMDD v2.0 hsa-miR-338-3p hepatocellular carcinoma inhibit cell migration|inhibit invasion 21671467 OncomiRDB hsa-miR-451a retinal neovascularization increased 18500251 HMDD v2.0 hsa-miR-326 multiple sclerosis miR-326 regulates TH-17 differentiation and is associated with the pathogenesis of multiple sclerosis 19838199 HMDD v2.0 hsa-miR-492 hepatoblastoma MicroRNA-492 is processed from the keratin 19 gene and up-regulated in metastatic hepatoblastoma. 21319197 HMDD v2.0 hsa-miR-375 squamous cell carcinoma Tumor suppressive microRNA-375 regulates oncogene AEG-1/MTDH in head and neck squamous cell carcinoma (HNSCC). 21753766 HMDD v2.0 hsa-miR-378f prostate cancer MiR-375, miR-378*, and miR-141 were significantly over-expressed in serum from CRPC patients compared with serum from low-risk localized patients, while miR-409-3p was significantly under-expressed. In prostate primary tumor samples, miR-375 and miR-141 also had significantly higher expression levels compared with those in normal prostate tissue. 22887127 HMDD v2.0 hsa-miR-508-3p renal cell carcinoma inhibit cell proliferation|induce apoptosis|inhibit cell migration 22369946 OncomiRDB hsa-miR-378b bladder carcinoma miR-10b, 19a, 126, 145, 221, 296-5p and 378 were significantly down-regulated in bladder carcinoma compared to adjacent normal urothelium. 22704449 HMDD v2.0 hsa-miR-4792 leiomyoma deregulated 22446413 HMDD v2.0 hsa-miR-107 lung cancer miR-107:we found significant overexpression of miR-103, miR-107, miR-301 and miR-338 in lung cancer cells as compared to HBECs 20624269 HMDD v2.0 hsa-miR-147b colorectal cancer down 23028787 dbDEMC v2.0 hsa-miR-542-5p lung cancer inhibit cell growth 22426479 OncomiRDB hsa-miR-498 cancer 1,25-Dihydroxyvitamin D3 suppresses telomerase expression and human cancer growth through microRNA-498 23055531 HMDD v2.0 hsa-miR-760 colorectal cancer miR-186, miR-216b, miR-337-3p, and miR-760 cooperatively induce cellular senescence by targeting alpha subunit of protein kinase CKII in human colorectal cancer cells 23137536 HMDD v2.0 hsa-miR-133b pancreatic cancer downregulated, Up-regulation leads to the reversal of EMT 19654291 HMDD v2.0 hsa-miR-663a acute myeloid leukemia Retinoic acid induces HL-60 cell differentiation via the upregulation of miR-663 21518431 HMDD v2.0 hsa-miR-326 type 1 diabetes mellitus Increased expression of microRNA miR-326 in type 1 diabetic patients with ongoing islet autoimmunity. 22069274 HMDD v2.0 hsa-miR-3163 glioblastoma Significantly deregulated miRNAs were miR-3163 (fold change 2.0, p = 0.05), miR-539 (fold change 0.5, p = 0.001), miR-1305 (fold change 0.5, p = 0.05), miR-1260 (fold change 0.5, p = 0.03) and let-7a (fold change 0.3, p = 0.02) after temozolomide treatment. 22074483 HMDD v2.0 hsa-miR-320d hepatocellular carcinoma This miRNA was down-regulated in HepG2 cells treated with BJA32515. 22027761 HMDD v2.0 hsa-miR-17-5p breast cancer up 21364938 dbDEMC v2.0 hsa-miR-451a diabetic nephropathies MicroRNA-451 regulates p38 MAPK signaling by targeting of Ywhaz and suppresses the mesangial hypertrophy in early Diabetic Nephropathies. 21827757 HMDD v2.0 hsa-miR-198 hepatocellular carcinoma inhibit cell proliferation|inhibit cell migration 23391410 OncomiRDB hsa-miR-206 B-cell chronic lymphocytic leukemia mutation 16251535 HMDD v2.0 hsa-miR-636 multiple myeloma miR-130b, miR-181a, and miR-636 to be differentially expressed between GC-sensitive and GC-resistant MM.1 cell lines. 21761344 HMDD v2.0 hsa-miR-206 colorectal cancer Increased expression of miR-21, mir-135a and miR-335 was associated with clinical progression of CRC (colorectal cancer), while miR-206 demonstrated an opposite trend. The levels of mir-21 did not associate with the expression of PTEN, an important tumour suppressor in CRC and one of many putative targets of miR-21, but interestingly was associated with stage of disease in the PTEN expressing tumours. Surprisingly, let7a, a KRAS-targeting miR, showed elevated expression in metastatic disease compared to normal mucosa or non-metastatic disease, and only in KRAS mutation positive tumors. Finally, a prognostic signature of miR 21,135a, 335, 206 and let-7a for detecting the presence of metastases had a specificity of 87% and sensitivity of 76% for the presence of metastases. 22120473 HMDD v2.0 hsa-miR-200c-3p ovarian cancer up 24512620 dbDEMC v2.0 hsa-miR-1246 colon cancer up 24239208 dbDEMC v2.0 hsa-miR-137 melanoma MicroRNA-137 Targets Carboxyl-terminal Binding Protein 1 in Melanoma Cell Lines. 21278922 HMDD v2.0 hsa-miR-378i bladder carcinoma hsa-miR-29c, hsa-miR-200a, hsa-miR-378, hsa-miR-429, hsa-miR-200c and hsa-miR-141 were up-regulated, while hsa-miR-451 was down-regulated. 22886973 HMDD v2.0 hsa-miR-492 hepatocellular carcinoma This miRNA was down-regulated in HepG2 cells treated with BJA32515. 22027761 HMDD v2.0 hsa-miR-198 lung cancer Circulating;Downregulation of cell-free miR-198 as a diagnostic biomarker for lung adenocarcinoma-associated malignant pleural effusion 23354517 HMDD v2.0 hsa-miR-608 Kaposi's sarcoma We show a direct repression of vIL-6 by hsa-miR-1293 and hIL-6 by hsa-miR-608. The repression of vIL-6 by miR-1293 was reversed by disruption of the vIL-6 miR-1293 seed match through the introduction of point mutations. In addition, expression of vIL-6 or hIL-6 in KSHV-infected cells could be enhanced by transfection of the respective miRNA inhibitors. In situ hybridization of human lymph node sections revealed that miR-1293 is primarily expressed in the germinal centre but is deficient in the mantle zone of lymph nodes, where the expression of vIL-6 is often found in patients with KSHV-associated multicentric Castleman's disease, providing evidence of an anatomical correlation. 21984125 HMDD v2.0 hsa-miR-518b lupus vulgaris miR-518b: downregulation 18998140 HMDD v2.0 hsa-miR-107 gastric cancer inhibit cell proliferation|induce cell cycle G1 arrest|inhibit cell invasion 21264532 OncomiRDB hsa-miR-206 breast cancer inhibit Eralpha signaling 19684618 HMDD v2.0 hsa-miR-1258 non small cell lung cancer The miR-1258 regulates the expression level of HPSE to influence the morbidity and metastasis of NSCLC. 22488243 HMDD v2.0 hsa-miR-133b thyroid carcinoma miR-146b, miR-221, miR-222, miR-155, miR-31 upregulation and miR-1, miR-34b, miR-130b, miR-138 downregulation in aggressive compared with nonaggressive PTC. 21537871 HMDD v2.0 hsa-miR-361-5p cutaneous squamous cell carcinoma NPA 23166713 OncomiRDB hsa-miR-133b myocardial infarction The miR-133 levels in plasma from AMI patients exhibited a 4.4-fold increase compared with control subjects (p=0.006). Moreover, the increased miR-133 levels in whole blood were comparable with those in plasma samples. 21881276 HMDD v2.0 hsa-miR-3179 pulmonary tuberculosis Overexpression 22900099 HMDD v2.0 hsa-miR-200b-3p endometrial adenocarcinoma NPA 23205572 OncomiRDB hsa-miR-133b cardiac myocytes MicroRNA-133 regulates the expression of GLUT4 by targeting KLF15 and is involved in metabolic control in cardiac myocytes 19720047 HMDD v2.0 hsa-miR-184 retinal neovascularization decreased 18500251 HMDD v2.0 hsa-miR-486-5p adrenocortical carcinoma down 20484036 dbDEMC v2.0 hsa-miR-502-5p colorectal cancer inhibit autophagy|inhibit cell growth|inhibit cell cycle progression|inhibit tumor growth 22580605 OncomiRDB hsa-miR-331-3p NPA reduce Akt signaling 20931396 OncomiRDB hsa-miR-302e head and neck cancer Hyaluronan-CD44v3 interaction with Oct4/Sox2/Nanog promotes miR-302 expression leading to self-renewal, clonal formation and cisplatin resistance in cancer stem cells from head and neck squamous cell carcinoma. 22847005 HMDD v2.0 hsa-miR-326 lung cancer miR-326 associates with biochemical markers of bone turnover in lung cancer bone metastasis 23142363 HMDD v2.0 hsa-miR-125a-5p lung cancer suppress cell proliferation|induce apoptosis 21777146 OncomiRDB hsa-miR-608 colorectal cancer In patients with stage III disease, mir608: rs4919510 was associated with increased risk for both recurrence and death. 22661538 HMDD v2.0 hsa-miR-658 lupus vulgaris miR-658: upregulation 18998140 HMDD v2.0 hsa-miR-17-5p lung cancer inhibit apoptosis 17384677 OncomiRDB hsa-miR-125a-3p gastric cancer inhibit cell proliferation 22322911 OncomiRDB hsa-miR-375 gastric cancer A high frequency recurrence and poor survival were observed in gastric cancer cases with high level of hsa-miR-375 and low level of hsa-miR-142-5p (P < 0.001). The results indicate that the combination of hsa-miR-375 and hsa-miR-142-5p as a predictor of disease progression has the potential to predict recurrence risk for GC patients. 21343377 HMDD v2.0 hsa-miR-595 colon cancer up 24239208 dbDEMC v2.0 hsa-miR-107 gastric cancer overexpressed 16461460 HMDD v2.0 hsa-miR-429 NPA increase drug sensitivity|increase drug-induced apoptosis 21993663 OncomiRDB hsa-miR-600 lupus vulgaris miR-600: upregulation 18998140 HMDD v2.0 hsa-miR-492 colorectal cancer mir-492:In a univariate analysis, the progression-free survival of the patients with the combined mir492 C/G and G/G genotype was significantly worse than that of the patients with the mir492 C/C genotype (rs2289030) (P value = 0.0426) 20044760 HMDD v2.0 hsa-miR-485-3p hepatocellular carcinoma promote cell growth|increase apoptosis|increase cell invasion 23468134 OncomiRDB hsa-miR-346 rheumatoid arthritis deregulated 22100329 HMDD v2.0 hsa-miR-429 adenocarcinoma regulate EP300, a metastasis suppressor gene; these miRs are related to reduced EP300 mRNA and protein; 19569050 HMDD v2.0 hsa-miR-184 eye abnormalities Bi-directional sequencing identified a single-base substitution +57C>T in miR-184. This variation segregated with the disease phenotype and was absent in the 1000 Genomes project, 1130 control chromosomes, and 28 non-human vertebrates.Conclusion:The single-base pair substitution in the seed region of miR-184 is responsible for the disease phenotype observed in EDICT syndrome. 22131394 HMDD v2.0 hsa-miR-346 schizophrenia miR-346: Expression of both miR-346 and GRID1 is lower in SZ patients than that in normal controls 19264453 HMDD v2.0 hsa-miR-378g bladder carcinoma hsa-miR-29c, hsa-miR-200a, hsa-miR-378, hsa-miR-429, hsa-miR-200c and hsa-miR-141 were up-regulated, while hsa-miR-451 was down-regulated. 22886973 HMDD v2.0 hsa-miR-326 brain cancer down 18973228 dbDEMC v2.0 hsa-miR-107 gastrointestinal cancer miR-107 targets cyclin-dependent kinase 6 expression, induces cell cycle G1 arrest and inhibits invasion in gastric cancer cells. 21264532 HMDD v2.0 hsa-miR-200a-5p ovarian cancer up 24512620 dbDEMC v2.0 hsa-miR-922 frontotemporal lobar degeneration miR-922 was significantly dysregulated in frontal cortex and cerebellar tissue samples of PGRN mutation carriers. 22032330 HMDD v2.0 hsa-miR-133b gastrointestinal cancer Fascin-1 overexpression and miR-133b downregulation in the progression of gastrointestinal stromal tumor 23196799 HMDD v2.0 hsa-miR-378f bladder carcinoma miR-10b, 19a, 126, 145, 221, 296-5p and 378 were significantly down-regulated in bladder carcinoma compared to adjacent normal urothelium. 22704449 HMDD v2.0 hsa-miR-217 hepatocellular carcinoma This miRNA was up-regulated in HepG2 cells treated with BJA32515. 22027761 HMDD v2.0 hsa-miR-636 myelodysplastic syndromes hsa-miR-378, hsa-miR-632, and hsa-miR-636 demonstrated particularly high discrimination between MDS and normal controls. 21703983 HMDD v2.0 hsa-miR-375 glioma Correlation of microRNA-375 downregulation with unfavorable clinical outcome of patients with glioma 23103713 HMDD v2.0 hsa-miR-320c hepatocellular carcinoma This miRNA was down-regulated in HepG2 cells treated with BJA32515. 22027761 HMDD v2.0 hsa-miR-449a adenocarcinoma miR-449: upregulated 19077565 HMDD v2.0 hsa-miR-320a colorectal cancer microRNA-320a inhibits tumor invasion by targeting neuropilin 1 and is associated with liver metastasis in colorectal cancer. 22134529 HMDD v2.0 hsa-miR-129-5p hepatocellular carcinoma inhibit tumor growth|increase apoptosis|inhibit cell migration 22536440 OncomiRDB hsa-miR-17-5p hepatocellular carcinoma promote cell proliferation|promote cell migration 20209605 OncomiRDB hsa-miR-1323 breast cancer The miRNA is up-regulated in whole blood of breast cancer patients 22242178 HMDD v2.0 hsa-miR-125a-5p lymphoma up 19846888 dbDEMC v2.0 hsa-miR-298 stroke correlate(pregulated or downregulated) 19724284 HMDD v2.0 hsa-miR-375 cervical cancer miR-375, Down-Regulated in Squamous Cervical Cancer, Inhibits Cell Migration and Invasion via Targeting Transcription Factor SP1. 21945323 HMDD v2.0 hsa-miR-184 neuroblastoma induce apoptosis|inhibit cell proliferation 20409325 OncomiRDB hsa-miR-133b bladder carcinoma inhibit cell proliferation|inhibit cell migration|inhibit cell invasion 23206218 OncomiRDB hsa-miR-30a-5p colon cancer inhibit cell growth|induce cell cycle G1 arrest|induce apoptosis 22287560 OncomiRDB hsa-miR-320a myasthenia gravis MiR-320a is Downregulated in Patients with Myasthenia Gravis and Modulates Inflammatory Cytokines Production by Targeting Mitogen-activated Protein Kinase 1 23196978 HMDD v2.0 hsa-miR-199a-3p hepatocellular carcinoma suppress tumor growth 21316602 OncomiRDB hsa-miR-107 breast cancer stem-like cells inhibit cancer stem cell growth 22908280 OncomiRDB hsa-miR-421 gastric cancer MiR-421 is a functional marker of circulating tumor cells in gastric cancer patients. 22263628 HMDD v2.0 hsa-miR-199a-5p melanoma promote metastatic invasion|promote angiogenesis|promote colonization 23142051 OncomiRDB hsa-miR-200b-3p ovarian cancer up 24512620 dbDEMC v2.0 hsa-miR-346 rheumatoid arthritis miR-346 Controls Release of TNF-a Protein and Stability of Its mRNA in Rheumatoid Arthritis via Tristetraprolin Stabilization. 21611196 HMDD v2.0 hsa-miR-107 acute promyelocytic leukemia NPA 17260024 OncomiRDB hsa-miR-661 breast cancer inhibit cell motility|inhibit cell invasion|inhibit cell growth|inhibit tumorigenicity 19584269 OncomiRDB hsa-miR-199b-3p hepatocellular carcinoma suppress tumor growth 21316602 OncomiRDB hsa-miR-30a-3p kidney cancer down 24189146 dbDEMC v2.0 hsa-miR-384 myocardial ischemia MicroRNA-384-5p regulates ischemia-induced cardioprotection by targeting phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit delta (PI3Kp110¦Ä) 23315007 HMDD v2.0 hsa-miR-378d bladder carcinoma hsa-miR-29c, hsa-miR-200a, hsa-miR-378, hsa-miR-429, hsa-miR-200c and hsa-miR-141 were up-regulated, while hsa-miR-451 was down-regulated. 22886973 HMDD v2.0 hsa-miR-199b-5p breast cancer inhibit cel migration|inhibit clonogenicity 23296799 OncomiRDB hsa-miR-139-5p colorectal cancer down 23028787 dbDEMC v2.0 hsa-miR-520b endometriosis A microRNA-520 mirSNP at the MMP2 gene influences susceptibility to endometriosis in Chinese women 23364396 HMDD v2.0 hsa-miR-133b lung cancer induce apoptosis following gemcitabine exposure 19654003 OncomiRDB hsa-miR-147b biliary tract cancer The miRNA was significantly more highly expressed in the malignant group than in the benign group. 21858175 HMDD v2.0 hsa-miR-566 colon cancer down 24921248 dbDEMC v2.0 hsa-miR-206 laryngeal cancer Down-regulation of MiR-206 Promotes Proliferation and Invasion of Laryngeal Cancer by Regulating VEGF Expression. 22110210 HMDD v2.0 hsa-miR-200a-3p ovarian cancer up 24512620 dbDEMC v2.0 hsa-miR-375 gastric cancer down 25167801 dbDEMC v2.0 hsa-miR-661 squamous cell carcinoma miR-146b alone have the strongest prediction accuracy for stratifying prognostic groups; 19584273 HMDD v2.0 hsa-miR-638 brain cancer down 21156648 dbDEMC v2.0 hsa-miR-622 lung cancer inhibit cell proliferation|induce cell cycle G0 arrest|inhibit colony formation 22016468 OncomiRDB hsa-miR-938 gastric cancer Genetic polymorphisms of IL17A ((rs2275913 (-197 G > A), rs3748067 (*1249 C > T)) and pri-microRNA-938 (pri-miR-938, rs2505901 (T > C).), targeting IL17A 3'-UTR, influence susceptibility to gastric cancer. 22537748 HMDD v2.0 hsa-miR-521 prostate cancer miR-521: Significant changes in Radiation modulation 18668526 HMDD v2.0 hsa-miR-1469 breast cancer The miRNA is down-regulated in whole blood of breast cancer patients 22242178 HMDD v2.0 hsa-miR-129-5p small intestinal neuroendocrine tumor down 23328977 dbDEMC v2.0 hsa-miR-429 ER+ breast cancer NPA 22101269 OncomiRDB hsa-miR-622 lupus vulgaris miR-622: upregulation 18998140 HMDD v2.0 hsa-miR-650 heart failure Six miRNAs were differently expressed when comparing D-HF (diabetic HF) and ND-HF (nondiabetic HF) patients: miR-34b, miR-34c, miR-199b, miR-210, miR-650, and miR-223. 22427379 HMDD v2.0 hsa-miR-4321 pancreatic cancer up 23155457 dbDEMC v2.0 hsa-miR-137 uveal melanoma induce cell cycle G1 arrest|decrease cell growth 21051724 OncomiRDB hsa-miR-375 head and neck squamous cell carcinoma inhibit cell invasion 22234174 OncomiRDB hsa-miR-137 melanoma miR-137:Our data show that miR-148 and miR-137 present an additional level of regulating Mitf expression in melanocytes and melanoma cells. 20644734 HMDD v2.0 hsa-miR-198 lung cancer downregulation 16530703 HMDD v2.0 hsa-miR-449a breast cancer up 21364938 dbDEMC v2.0 hsa-miR-663a breast cancer Treatment with E2, BPA and DDT decreased (p<0.05) miR-21 expression. Several members of the let-7 family (let-7a, let-7b, let-7c, let-7d, let-7e and let-7f), were downregulated (p<0.05) by all three treatments.and miR-15b (p<0.005) and miR-27b (p<0.01) were also downregulated by the three treatments.upregulation of miR-638 (P<0.005), miR-663 (P<0.005), and miR-1915 (P<0.005) was observed after treatment of MCF7 cells with E2, BPA or DDT 22403704 HMDD v2.0 hsa-miR-302f head and neck cancer Hyaluronan-CD44v3 interaction with Oct4/Sox2/Nanog promotes miR-302 expression leading to self-renewal, clonal formation and cisplatin resistance in cancer stem cells from head and neck squamous cell carcinoma. 22847005 HMDD v2.0 hsa-miR-622 colorectal cancer up 21844009 dbDEMC v2.0 hsa-miR-520e hepatocellular carcinoma A novel tumor suppressor miRNA miR-520e contributes to suppression of hepatoma. 22212428 HMDD v2.0 hsa-miR-147b colorectal cancer differentially expressed 22850566 HMDD v2.0 hsa-miR-147a breast cancer miR-124, miR-147 and miR-193a-3p are three novel tumor suppressors that co-target EGFR-driven cell-cycle network proteins and inhibit cell-cycle progression and proliferation in breast cancer. 22333974 HMDD v2.0 hsa-miR-107 colon cancer inhibit hypoxic signaling|suppress tumor angiogenesis|suppress tumor growth 20308559 OncomiRDB hsa-miR-320a interstitial cystitis demonstrate a direct correlation between miR-449b, miR-500, miR-328, and miR-320 and a down-regulation of NK1R mRNA and/or protein levels 20008142 HMDD v2.0 hsa-miR-206 lung cancer MicroRNA-206 Is Associated With Invasion and Metastasis of Lung Cancer. 21157919 HMDD v2.0 hsa-miR-484 hepatocellular carcinoma This miRNA was down-regulated in HepG2 cells treated with BJA32515. 22027761 HMDD v2.0 hsa-miR-206 myotonic dystrophy microRNA-206:Overexpression of microRNA-206 in the skeletal muscle from myotonic dystrophy type 1 patients 20487562 HMDD v2.0 hsa-miR-17-5p gastric cancer promote cell cycle progression|inhibit apoptosis 23333058 OncomiRDB hsa-miR-107 pancreatic cancer inhibit cell growth 19407485 OncomiRDB hsa-miR-575 brain cancer down 19703993 dbDEMC v2.0 hsa-miR-421 biliary tract cancer MicroRNA-421 functions as an oncogenic miRNA in biliary tract cancer through down-regulating farnesoid X receptor expression. 22146319 HMDD v2.0 hsa-miR-133b hepatocellular carcinoma This miRNA was down-regulated in HepG2 cells treated with BJA32515. 22027761 HMDD v2.0 hsa-miR-151b renal cell carcinoma miR-151-30: Up-regulated in the blook serum of patients with renal cell carcinoma compared to healthy controls. 22440013 HMDD v2.0 hsa-miR-137 schizophrenia GWAS analysis revealed that rs1625579 within an intron of a putative primary transcript for MIR137 (microRNA 137), a known regulator of neuronal development was associated with schizophrenia. 21926974 HMDD v2.0 hsa-miR-548a-5p NPA NPA 21057533 OncomiRDB hsa-miR-509-5p leukemia up 25368993 dbDEMC v2.0 hsa-miR-514b-5p ovarian cancer up 24512620 dbDEMC v2.0 hsa-miR-320a colorectal cancer MicroRNA-320a suppresses human colon cancer cell proliferation by directly targeting beta-catenin. 22459450 HMDD v2.0 hsa-miR-429 iga glomerulonephritis down-regulated 20364043 HMDD v2.0 hsa-miR-338-5p colorectal cancer up 23758639 dbDEMC v2.0 hsa-miR-107 prostate cancer miR-107 and miR-574-3p were quantified at significantly higher concentrations in the urine of men with prostate cancer compared with controls. 22240788 HMDD v2.0 hsa-miR-509-3-5p ovarian cancer up 24512620 dbDEMC v2.0 hsa-miR-429 learned helplessness mir-96, 141, 182, 183, 183*, 298, 200a, 200a*, 200b, 200b*, 200c, 429 are significantly downregulated in non-learned helplessness relative to tested controls in rat brain. 21275079 HMDD v2.0 hsa-miR-663a burns miR-663 was up-regulated in denatured dermis compared with those in normal skin. 22360957 HMDD v2.0 hsa-miR-133b hypertension MiR-296-5p (Fold change 0.47, P = 0.013) and miR-133b (Fold change 0.57, P = 0.033) were consistently down-regulated in the patient plasma, whereas let-7e (Fold change 1.62, P = 0.009) and hcmv-miR-UL112 (Fold change 2.72, P = 0.004), one human cytomegalovirus encoded microRNAs, were up-regulated in the patient samples. 21924071 HMDD v2.0 hsa-miR-2861 basal cell carcinoma downregulated in the tumor center 22540308 HMDD v2.0 hsa-miR-421 gastric cancer increase cell growth 19802518 OncomiRDB hsa-miR-941 ulcerative colitis UC susceptibility 22359580 HMDD v2.0 hsa-miR-324-5p brain cancer down 18973228 dbDEMC v2.0 hsa-miR-1179 colorectal cancer miR-150*, miR-125b-2*, miR-1179 and miR-139-3p were up-regulated in colorectal cancers with liver metastasis 21174058 HMDD v2.0 hsa-miR-378e basal cell carcinoma downregulated in the tumor center 22540308 HMDD v2.0 hsa-miR-375 cancer MicroRNA-375 is downregulated in gastric cancers 20215506 HMDD v2.0 hsa-miR-572 basal cell carcinoma downregulated in the tumor center 22540308 HMDD v2.0 hsa-miR-429 endometrial cancer Luciferase assays and Western blot analysis demonstrated that the miR-200b/200c/429 family recognized the MRE in the 3' UTR of AP-2¦Á gene and negatively regulated the expression of endogenous AP-2¦Á proteins. SNP rs1045385 A>C variation enhanced AP-2¦Á expression by disrupting the binding of the miR-200b/200c/429 family to the 3' UTR of AP-2¦Á. The effects of the two polymorphic variants on cisplatin sensitivity were determined by clonogenic assay. The overexpression of AP-2¦Á with mutant 3' UTR (C allele) in the endometrial cancer cell line HEC-1A, which has high levels of endogenous miR-200b/200c/429 and low levels of AP-2¦Á protein, significantly increased cisplatin sensitivity, but overexpression of A allele of AP-2¦Á has no significant effects, compared with mock transfection. We concluded that miR-200b/200c/429 induced cisplatin resistance by repressing AP-2¦Á expression in endometrial cancer cells. The SNP (rs1045385) A>C variation decreased the binding of miR-200b/200c/429 to the 3' UTR of AP-2¦Á, which upregulated AP-2¦Á protein expression and increased cisplatin sensitivity. Our results suggest that SNP (rs1045385) may be a potential prognostic marker for cisplatin treatment. 22194984 HMDD v2.0 hsa-miR-133b cervical cancer promote cell proliferation|promote colony formation|promote tumorigenesis|promote lung metastasis 22179829 OncomiRDB hsa-miR-133b atrial fibrillation both miR-133 and miR-30 play an important role in controlling structural changes in chronic AF 22407060 HMDD v2.0 hsa-miR-133b testicular cancer downregulated 19946373 HMDD v2.0 hsa-miR-320a TEL-AML1+ leukemia induce apoptosis 20807887 OncomiRDB hsa-miR-342-5p lymphoma down 21921041 dbDEMC v2.0 hsa-miR-206 breast cancer inhibit cell growth|block cell cycle G1/S transition|inhibit cell proliferation|inhibit colony formation 23466356 OncomiRDB hsa-miR-34c-5p non small cell lung cancer increase the resistance of paclitaxel-induced apoptosis 22370637 OncomiRDB hsa-miR-526a breast cancer The miRNA is down-regulated in whole blood of breast cancer patients 22242178 HMDD v2.0 hsa-miR-335-5p sarcoma up 25784290 dbDEMC v2.0 hsa-miR-596 ependymoma Three miRNAs (let-7d, miR-596 and miR-367) strongly correlate to overall survival. 22053178 HMDD v2.0 hsa-miR-1322 esophageal cancer miR-1322 could significantly down-regulate the ECRG2 with TCA3 allele (P??0.05). MicroRNA-1322 regulates ECRG2 allele specifically and acts as a potential biomarker in patients with esophageal squamous cell carcinoma. 22315007 HMDD v2.0 hsa-miR-34c-3p lung cancer up 22331473 dbDEMC v2.0 hsa-miR-320c hepatocellular carcinoma hsa-miR-320c was down-regulated in HepG2 cells after 5 hours of culture with grape seed proanthocyanidin extract. 21998738 HMDD v2.0 hsa-miR-662 lupus vulgaris miR-662: upregulation 18998140 HMDD v2.0 hsa-miR-518b lymphoma A distinct set of five microRNAs (miR-150, miR-550, miR-124a, miR-518b and miR-539) was shown to be differentially expressed in gastritis as opposed to MALT lymphoma. 22395483 HMDD v2.0 hsa-miR-591 gastric cancer A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemoresistance 22112324 HMDD v2.0 hsa-miR-375 adrenocortical carcinoma miR-375: upregulated 19351815 HMDD v2.0 hsa-miR-507 heart failure downregulated 17606841 HMDD v2.0 hsa-miR-103b schizophrenia miR-181b, miR-219-2-3p, miR-346, miR-195, miR-1308, miR-92a, miR-17, miR-103 and let-7g are the key players to reflect the schizophrenia illnesses status and may serve as candidate biomarkers for diagnosis of schizophrenia. In addition, we also found that the risperidone improved the serum miR-346 level of schizophrenia significantly, and therefore may not be an effective drug in regulating serum miR-346 level of schizophrenia. 22094284 HMDD v2.0 hsa-miR-557 Ewing sarcoma MiR-21, miR-31, miR-31*, miR-106b, miR-145, miR-150*, miR-371-5p, miR-557 and miR-598 showed recurrently altered expression. 22429812 HMDD v2.0 hsa-miR-147b pulmonary tuberculosis Overexpression 22900099 HMDD v2.0 hsa-miR-429 renal cell carcinoma miR-429: down-regulated in malignant cancer than non-malignant one 19228262 HMDD v2.0 hsa-miR-451a esophageal cancer Effect of miR-451 on the Biological Behavior of the esophageal cancer Cell Line EC9706 23053883 HMDD v2.0 hsa-miR-346 lupus vulgaris miR-346: downregulation 18998140 HMDD v2.0 hsa-miR-184 renal cell carcinoma miR-184 show abnormal expression in human renal carcinoma. 21844955 HMDD v2.0 hsa-miR-378i renal cell carcinoma The level of miR-378 was significantly increased in serum of ccRCC patients. 22542158 HMDD v2.0 hsa-miR-375 endometriosis down-regulated in endometriomas compared with endometrium. 21436257 HMDD v2.0 hsa-miR-451b non small cell lung cancer Plasma miR-21, miR-30d, miR-451, miR-10a, miR-30e-5p and miR-126*, miR-126, miR-145) were differentially expressed 23756108 HMDD v2.0 hsa-miR-375 prostate cancer up 19676045 dbDEMC v2.0 hsa-miR-429 endometriosis down-regulated in endometriomas compared with endometrium. 21436257 HMDD v2.0 hsa-miR-640 gastric cancer A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemoresistance 22112324 HMDD v2.0 hsa-miR-378g prostate cancer MiR-375, miR-378*, and miR-141 were significantly over-expressed in serum from CRPC patients compared with serum from low-risk localized patients, while miR-409-3p was significantly under-expressed. In prostate primary tumor samples, miR-375 and miR-141 also had significantly higher expression levels compared with those in normal prostate tissue. 22887127 HMDD v2.0 hsa-miR-542-3p lung cancer inhibit cell proliferation|induce cell cycle G1 & G2/M arrest 20728447 OncomiRDB hsa-miR-133b left ventricular hypertrophy miR-133 and miR-30 regulate connective tissue growth factor: implications for a role of microRNAs in myocardial matrix remodeling 19096030 HMDD v2.0 hsa-miR-520e non small cell lung cancer The authors found a number of miRNAs (miR-17, miR-135, miR-520, miR-124-1, and miR-34c) that may rescue cell viability from caspase-8 activation. 22370637 HMDD v2.0 hsa-miR-429 bladder carcinoma Compared to matched histologically normal urothelium, upregulated. 21464941 HMDD v2.0 hsa-miR-571 renal cell carcinoma Up-regulated in the blook serum of patients with renal cell carcinoma compared to healthy controls. 22440013 HMDD v2.0 hsa-miR-608 breast cancer Polymorphism rs4919510:C>G in mature sequence of human microRNA-608 contributes to the risk of HER2-positive breast cancer but not other subtypes. 22586447 HMDD v2.0 hsa-miR-449a prostate cancer induce Rb-dependent cell cycle arrest|induce Rb-dependent senescence 20948989 OncomiRDB hsa-miR-137 breast cancer MiR-137 targets estrogen-related receptor alpha and impairs the proliferative and migratory capacity of breast cancer cells. 22723937 HMDD v2.0 hsa-miR-520e endometriosis A microRNA-520 mirSNP at the MMP2 gene influences susceptibility to endometriosis in Chinese women 23364396 HMDD v2.0 hsa-miR-429 ovarian cancer Higher 18451233 HMDD v2.0 hsa-miR-375 barrett esophagus The authors propose miR-31 and -375 as novel candidate microRNAs specifically associated with early- and late-stage malignant progression, respectively, in Barrett's esophagus. 22302717 HMDD v2.0 hsa-miR-711 adult T cell leukemia induced 21865341 HMDD v2.0 hsa-miR-133b brain cancer down 18973228 dbDEMC v2.0 hsa-miR-422a melanoma miR-422a:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients 20529253 HMDD v2.0 hsa-miR-107 melanoma miR-107:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients 20529253 HMDD v2.0 hsa-miR-449a colon cancer miR-449:In particular, miR-126, miR-142-3p, miR-155, miR-552, and miR-630 were all upregulated, whereas miR-146a, miR-152, miR-205, miR-365, miR-449, miR-518c, miR-584, miR-615, and miR-622 were downregulated after NGX6 transfection. 20859756 HMDD v2.0 hsa-miR-107 Alzheimer's disease microRNAs 103 and 107 repress translation of cofilin, and that reduced levels of miR-103 or miR-107 are associated with elevated cofilin protein levels and formation of rod-like structures in a transgenic mouse model of AD 21179570 HMDD v2.0 hsa-miR-638 lymphoma up 24121164 dbDEMC v2.0 hsa-miR-346 schizophrenia miR-181b, miR-219-2-3p, miR-346, miR-195, miR-1308, miR-92a, miR-17, miR-103 and let-7g are the key players to reflect the schizophrenia illnesses status and may serve as candidate biomarkers for diagnosis of schizophrenia. In addition, we also found that the risperidone improved the serum miR-346 level of schizophrenia significantly, and therefore may not be an effective drug in regulating serum miR-346 level of schizophrenia. 22094284 HMDD v2.0 hsa-miR-206 neuroblastoma inhibit cell proliferation|induce apoptosis 22508046 OncomiRDB hsa-miR-638 hepatitis c miR-24, miR-149, miR-638 and miR-1181 were identified to be involved in HCV entry, replication and propagation 20006370 HMDD v2.0 hsa-miR-151b gastric cancer Plasma miRNA-199a-3p and miRNA-151-5p were significantly elevated (p < 0.05) and were significantly reduced after surgery (p < 0.05) in gastric cancer patients. 22956063 HMDD v2.0 hsa-miR-206 breast cancer miR-206: down-regulated in estrogen receptor alpha-positive human breast cancer 18593897 HMDD v2.0 hsa-miR-346 hepatocellular carcinoma This miRNA was down-regulated in HepG2 cells treated with BJA32515. 22027761 HMDD v2.0 hsa-miR-490-3p hepatocellular carcinoma increase cell proliferation|increase cell migration|increase cell invasion|promote epithelial to mesenchymal transition 23212913 OncomiRDB hsa-miR-326 multiple sclerosis Four miRNAs (miR-326, miR-155, miR-146a, miR-142-3p) were aberrantly expressed in peripheral blood mononuclear cells from RRMS (relapsing remitting multiple sclerosis) patients compared to healthy controls. 21949733 HMDD v2.0 hsa-miR-133b prostate cancer inhibit cell proliferation|inhibit cell migration|inhibit cell invasion 22407299 OncomiRDB hsa-miR-375 squamous cell carcinoma Tumor suppressive microRNA-375 regulates lactate dehydrogenase B in maxillary sinus squamous cell carcinoma. 21922130 HMDD v2.0 hsa-miR-320b hepatocellular carcinoma This miRNA was down-regulated in HepG2 cells treated with BJA32515. 22027761 HMDD v2.0 hsa-miR-484 lupus vulgaris miR-484: downregulation 18998140 HMDD v2.0 hsa-miR-137 glioblastoma miR-137: miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cells 18577219 HMDD v2.0 hsa-miR-1183 rectal cancer Microarray analysis selected 14 miRNAs as being differentially expressed in TRG1 patients, and 13 were confirmed by qRT-PCR: 11 miRNAs (miR-1183, miR-483-5p, miR-622, miR-125a-3p, miR-1224-5p, miR-188-5p, miR-1471, miR-671-5p, miR-1909?, miR-630, miR-765) were significantly upregulated in TRG1 patients, 2 (miR-1274b, miR-720) were downexpressed. MiR-622 and miR-630 had a 100% sensitivity and specificity in selecting TRG1 cases. 22172905 HMDD v2.0 hsa-miR-217 leiomyoma deregulated 22446413 HMDD v2.0 hsa-miR-107 myotonic dystrophy These results support a role for miRNAs in DM1 pathogenesis, and, in particular, highlight mir-107 and mir-103 as attractive candidates for binding to DMPK. 17697356 HMDD v2.0 hsa-miR-107 astrocytoma miR-107, miR-124, miR-138, and miR-149 were downregulated significantly in grade I-IV astrocytomas, and overexpression of miR-124 and miR-149 inhibited glioblastoma cell proliferation and migration. 21978395 HMDD v2.0 hsa-miR-125a-3p non small cell lung cancer inhibit cell invasion|inhibit cell migration 20569443 OncomiRDB hsa-miR-638 colorectal cancer The miRNA has a role in colorectal liver metastases. 21722265 HMDD v2.0 hsa-miR-663a lupus nephritis miR-663:hsa-miR-371-5P, hsa-miR-423-5P, hsa-miR-638, hsa-miR-1224-3P and hsa-miR-663 that were differentially expressed in lupus nephritis across different racial groups and all specimen types tested 20485490 HMDD v2.0 hsa-miR-765 hepatocellular carcinoma hsa-miR-765 was down-regulated in HepG2 cells after 5 hours of culture with cocoa proanthocyanidin extract. 21998738 HMDD v2.0 hsa-miR-429 barrett esophagus miR-200 family expression is downregulated upon neoplastic progression of Barrett's esophagus. 21448356 HMDD v2.0 hsa-miR-184 lupus vulgaris miR-184: upregulation 18998140 HMDD v2.0 hsa-miR-429 pancreatic cancer Highly up-regulated in PDAC compared with normal ductal 21953293 HMDD v2.0 hsa-miR-133b chronic obstructive pulmonary disease A reduction in expression of miR-1 (2.5-fold, p=0.01) and the myocardin-related transcription factors (MRTFs) A and B was observed in patients compared with controls (MRTF-A mRNA: twofold, p=0.028; MRTF-B mRNA: fourfold, p=0.011). miR-1 expression was associated with smoking history, lung function, fat-free mass index, 6 min walk distance and percentage of type 1 fibres. miR-133 and miR-206 were negatively correlated with daily physical activity. Insulin-like growth factor 1 mRNA was increased in the patients and miR-1 was negatively correlated with phosphorylation of the kinase Akt. Furthermore, the protein levels of histone deacetylase 4, another miR-1 target, were increased in the patients. 21998125 HMDD v2.0 hsa-miR-146b-5p lymphoma down 21701491 dbDEMC v2.0 hsa-miR-184 gastric cancer The miR-184 Binding-Site rs8126 T>C Polymorphism in TNFAIP2 Is Associated with Risk of Gastric Cancer. 23724109 HMDD v2.0 hsa-miR-520h cancer miR-520h:Downregulation of microRNA miR-520h by E1A contributes to anticancer activity 20501832 HMDD v2.0 hsa-miR-133b squamous cell carcinoma miR-145, miR-133a and miR-133b: Tumor-suppressive miRNAs target FSCN1 in esophageal squamous cell carcinoma. 21351259 HMDD v2.0 hsa-miR-184 renal cell carcinoma miR-210, miR-184 and miR-206) play pivotal roles in ccRCC development 21253009 HMDD v2.0 hsa-miR-451a gastrointestinal cancer miR-451: microRNA-451 Regulates Macrophage Migration Inhibitory Factor Proliferation of Gastrointestinal Cancer Cells Production 19318487 HMDD v2.0 hsa-miR-137 oligodendroglioma MIR-137 Suppresses Growth and Invasion, is Downregulated in Oligodendroglial Tumors and Targets CSE1L 23252729 HMDD v2.0 hsa-miR-885-5p neuroblastoma inhibit cell proliferation|induce cell cycle arrest|induce senescence|induce apoptosis 21233845 OncomiRDB hsa-miR-199b-5p medulloblastoma inhibit cell proliferation 19308264 OncomiRDB hsa-miR-107 breast cancer up 24917463 dbDEMC v2.0 hsa-miR-520d-3p kidney cancer up 22871070 dbDEMC v2.0 hsa-miR-206 breast cancer The micro-ribonucleic acid (miRNA) miR-206 targets the human estrogen receptor-alpha (ERalpha) and represses ERalpha messenger RNA and protein expression in breast cancer cell lines. 17312270 HMDD v2.0 hsa-miR-451a bcr-abl positive chronic myelogenous leukemia Myc induced miR-144/451 contributes to the acquired imatinib resistance in chronic myelogenous leukemia cell K562. 22842456 HMDD v2.0 hsa-miR-663a leukemia miR-663: upregulated during human leukemic HL-60 cell differentiation induced by 4-hydroxynonenal 19022373 HMDD v2.0 hsa-miR-206 rhabdomyosarcoma miR-206:miR-206, as landmark biomarkers for RMS 20696132 HMDD v2.0 hsa-miR-486-5p oral cancer down 22761427 dbDEMC v2.0 hsa-miR-141-3p ovarian cancer up 24512620 dbDEMC v2.0 hsa-miR-137 colon cancer expressed differently, miR-137 upregulated in non-cancerous colonic tissues from colon cancer patients with lymph node metastasis 19659786 HMDD v2.0 hsa-miR-378h bladder carcinoma hsa-miR-29c, hsa-miR-200a, hsa-miR-378, hsa-miR-429, hsa-miR-200c and hsa-miR-141 were up-regulated, while hsa-miR-451 was down-regulated. 22886973 HMDD v2.0 hsa-miR-133b lymphoma up 19846888 dbDEMC v2.0 hsa-miR-542-3p NPA inhibit tumor growth 21860426 OncomiRDB hsa-miR-663b cancer Expression of human endogenous retrovirus-K coincides with that of micro-RNA-663 and -638 in germ-cell tumor cells 23155245 HMDD v2.0 hsa-miR-375 hepatocellular carcinoma inhibit autophagy under hypoxic conditions 22504094 OncomiRDB hsa-miR-449a EVI1+ myeloid leukemia induce apoptosis|reduce cell viability 21569010 OncomiRDB hsa-miR-636 hepatocellular carcinoma ANT2 suppression by shRNA restores miR-636 expression, thereby downregulating Ras and inhibiting tumorigenesis of hepatocellular carcinoma 23306701 HMDD v2.0 hsa-miR-378d bladder carcinoma miR-10b, 19a, 126, 145, 221, 296-5p and 378 were significantly down-regulated in bladder carcinoma compared to adjacent normal urothelium. 22704449 HMDD v2.0 hsa-miR-133b retinal degeneration miR-133: upregulation 18834879 HMDD v2.0 hsa-miR-19a-3p colon cancer up 24239208 dbDEMC v2.0 hsa-miR-133b heart failure expression decrease 19059107 HMDD v2.0 hsa-miR-184 lymphoma different expression between small lymphocytic leukemia and lymphoma 22490335 HMDD v2.0 hsa-miR-147a parkinson disease miR-147: differentially expressed in PBMCs (peripheral blood mononuclear cells) of PD patients and controls. 22003392 HMDD v2.0 hsa-miR-1260a glioblastoma Significantly deregulated miRNAs were miR-3163 (fold change 2.0, p = 0.05), miR-539 (fold change 0.5, p = 0.001), miR-1305 (fold change 0.5, p = 0.05), miR-1260 (fold change 0.5, p = 0.03) and let-7a (fold change 0.3, p = 0.02) after temozolomide treatment. 22074483 HMDD v2.0 hsa-miR-1246 esophageal cancer Serum;Serum microRNA expression profile: miR-1246 as a novel diagnostic and prognostic biomarker for oesophageal squamous cell carcinoma 23361059 HMDD v2.0 hsa-miR-142-5p leukemia up 23613318 dbDEMC v2.0 hsa-miR-193a-5p squamous cell carcinoma promote cell viability|dramaticly reduce chemosensitivity 21293058 OncomiRDB hsa-miR-1246 colorectal cancer The driving miRNAs were miR-195, miR-1280, miR-140-3p and miR-1246 in colorectal tumors. 22479426 HMDD v2.0 hsa-miR-520b gout There was a clear link between the rs1333049 genotypic and allelic frequencies between gout cases and controls. There was a significantly increased risk of gout in carriers of the CC genotype.This SNP is homologous to miR-519 and miR-520. 21558165 HMDD v2.0 hsa-miR-375 head and neck cancer down-regulation 22425712 HMDD v2.0 hsa-miR-375 breast cancer The miRNA was up-regulated during lobular neoplasia progression compared to normal epithelium. hsa-miR-375 is differentially expressed during breast lobular neoplasia and promotes loss of mammary acinar polarity. 21953071 HMDD v2.0 hsa-miR-375 head and neck cancer reduce cell viability|reduce clonogenic survival|inhibit cell migration|inhibit cell invasion 22031094 OncomiRDB hsa-miR-628-3p breast cancer up 24917463 dbDEMC v2.0 hsa-miR-429 nephrosclerosis significantly higher in patients with hypertensive nephrosclerosis than controls 19910931 HMDD v2.0 hsa-miR-297 sepsis Microarray analysis showed that serum miR-297 and miR-574-5p were differentially expressed in sepsis survivors and nonsurvivors. Upon validation with 118 sepsis patients' samples, these two miRNA expressions were significantly different, with P < 0.001. miR-297 was more closely associated with survival from sepsis, whereas miR-574-5p was associated with death from sepsis. 22344312 HMDD v2.0 hsa-miR-300 heart failure upregulated 17606841 HMDD v2.0 hsa-miR-342-3p colorectal cancer down 23758639 dbDEMC v2.0 hsa-miR-596 lupus vulgaris miR-596: downregulation 18998140 HMDD v2.0 hsa-miR-133b colorectal cancer inhibit cell proliferation|induce apoptosis 20505319 OncomiRDB hsa-miR-320c aging MicroRNA-199a-3p, microRNA-193b, and microRNA-320c are correlated to aging and regulate human cartilage metabolism. 22674437 HMDD v2.0 hsa-miR-326 brain cancer The neuronal microRNA miR-326 acts in a feedback loop with notch and has therapeutic potential against brain tumors 19955368 HMDD v2.0 hsa-miR-127-3p mucoepidermoid carcinoma inhibit cell viability|induce cell cycle G1/S arrest 23232714 OncomiRDB hsa-miR-339-5p breast cancer decrease cell migration|decrease cell invasion 20932331 OncomiRDB hsa-miR-449a hepatitis c Hepatitis C Virus Mediated Changes in miRNA-449a Modulates Inflammatory Biomarker YKL40 through Components of the NOTCH Signaling Pathway 23226395 HMDD v2.0 hsa-miR-451a adult T cell leukemia Repression of tumor suppressor miR-451 is essential for NOTCH1-induced oncogenesis in T-ALL. 21464222 HMDD v2.0 hsa-miR-17-5p colorectal cancer NPA 23250421 OncomiRDB hsa-miR-451a bcr-abl positive chronic myelogenous leukemia downregulated 21511335 HMDD v2.0 hsa-miR-193a-3p hepatocellular carcinoma promote cell proliferation|increase cell cycle|increase 5-FU resistance 22117060 OncomiRDB hsa-miR-451a bcr-abl positive chronic myelogenous leukemia miRNA-451 is a putative predictor marker of Imatinib therapy response in chronic myeloid leukemia. 21944890 HMDD v2.0 hsa-miR-217 pancreatic cancer altered expression 22114139 HMDD v2.0 hsa-miR-557 lupus vulgaris miR-557: downregulation 18998140 HMDD v2.0 hsa-miR-638 cancer Expression of human endogenous retrovirus-K coincides with that of micro-RNA-663 and -638 in germ-cell tumor cells 23155245 HMDD v2.0 hsa-miR-206 gastric cancer MiR-206 inhibits gastric cancer proliferation in part by repressing CyclinD2 23348698 HMDD v2.0 hsa-miR-300 ovarian cancer The miRNA was upregulated in cis-platin resistant (A2780/CP70) vs. cis-platin sensitive (A2780) ovarian cancer cell lines. 21939554 HMDD v2.0 hsa-miR-326 hepatocellular carcinoma This miRNA was down-regulated in HepG2 cells treated with BJA32515. 22027761 HMDD v2.0 hsa-miR-337-3p non small cell lung cancer increase taxane sensitivity 22723956 OncomiRDB hsa-miR-520h heart failure downregulated 17606841 HMDD v2.0 hsa-miR-638 gastric cancer up 25167801 dbDEMC v2.0 hsa-miR-378h prostate cancer MiR-375, miR-378*, and miR-141 were significantly over-expressed in serum from CRPC patients compared with serum from low-risk localized patients, while miR-409-3p was significantly under-expressed. In prostate primary tumor samples, miR-375 and miR-141 also had significantly higher expression levels compared with those in normal prostate tissue. 22887127 HMDD v2.0 hsa-miR-622 gastric cancer promote invasion|promote tumorigenesis|promote metastasis 21528065 OncomiRDB hsa-miR-206 rhabdomyosarcoma MicroRNA-206:MicroRNA-206 expression levels correlate with clinical behaviour of rhabdomyosarcomas 20502458 HMDD v2.0 hsa-miR-107 gastric cancer promote cell migration|promote cell invasion 21029372 OncomiRDB hsa-miR-107 glioma P53-induced microRNA-107 inhibits proliferation of glioma cells and down-regulates the expression of CDK6 and Notch-2 23220650 HMDD v2.0 hsa-miR-302f pre-eclampsia Six miRNAs were more than 2-fold over-expressed in severe preeclampsia: let-7b, miRNA-302*, miRNA-104, miRNA-128a, miRNA-182* and miRNA-133b. 21309633 HMDD v2.0 hsa-miR-638 basal cell carcinoma downregulated in the tumor center 22540308 HMDD v2.0 hsa-miR-451a glioblastoma A computational multiscale model of glioblastoma growth: Regulation of cell migration and proliferation via microRNA-451, LKB1 and AMPK 23367447 HMDD v2.0 hsa-miR-375 oral cancer MiR-375 is repressed and miR-127 activated in OSCC, and we confirm previous reports of miR-137 hypermethylation in oral cancer. The miR-200 s/miR-205 were epigenetically activated in tumors vs normal tissues, but repressed in the absence of DNA hypermethylation specifically in CD44(high) oral CSCs. Aberrant miR-375 and miR-200a expression and miR-200c-141 methylation could be detected in and distinguish OSCC patient oral rinse and saliva from healthy volunteers. 22132151 HMDD v2.0 hsa-miR-632 myelodysplastic syndromes hsa-miR-378, hsa-miR-632, and hsa-miR-636 demonstrated particularly high discrimination between MDS and normal controls. 21703983 HMDD v2.0 hsa-miR-1275 colorectal cancer The miRNA has a role in colorectal liver metastases. 21722265 HMDD v2.0 hsa-miR-107 lymphoma down 24121164 dbDEMC v2.0 hsa-miR-320e hepatocellular carcinoma This miRNA was down-regulated in HepG2 cells treated with BJA32515. 22027761 HMDD v2.0 hsa-miR-320a gastric cancer The levels of serum miR-20a-5p, let-7a and miR-320a were positively correlated with PGA/PGC, which may indirectly reflect the functional status of the gastric mucosa. 23521833 HMDD v2.0 hsa-miR-17-5p lung cancer up 19584273 dbDEMC v2.0 hsa-miR-608 colorectal cancer Two SNPs were identified to be significantly associated with recurrence-free survival and overall survival of the patients. The most significant SNP was rs6505162 in pre-miR-423. Compared to the homozygous wild-type genotype, the variant-containing genotypes of this SNP were significantly associated with both the overall survival (HR=2.12, 95% CI1.34--3.34, P=0.001) and the recurrence-free survival (HR=1.59, 95% CI1.08--2.36, P=0.019). Another SNP, rs4919510 in pre-miR-608, was also associated with altered recurrence-free survival (HR=0.61, 95% CI 0.41-0.92, P=0.017). These effects were evident only in patients receiving chemotherapy but not in those without chemotherapy. In addition, the combined analysis of the two SNPs conferred a 2.84-fold (95% CI 1.50-5.37, P=0.001) increased risk of recurrence and/or death. Similarly, this effect was only prominent in those receiving chemotherapy (P<0.001) but not in those without chemotherapy (P=0.999). 22028396 HMDD v2.0 hsa-miR-421 hepatocellular carcinoma promote cell proliferation|promote cell migration|promote invasion of HCC cells 22446874 OncomiRDB hsa-miR-320c adenoviridae infections miR-320c-2:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control 20634878 HMDD v2.0 hsa-miR-935 medulloblastoma hsa-miR-935 was significantly down-regulated in primary Medulloblastoma specimens relative to CD133+ NSCs (Neural Stem Cells). 21931624 HMDD v2.0 hsa-miR-1299 ovarian cancer The miRNA was upregulated in cis-platin resistant (A2780/CP70) vs. cis-platin sensitive (A2780) ovarian cancer cell lines. 21939554 HMDD v2.0 hsa-miR-17-5p breast cancer inhibit cell proliferation 16940181 OncomiRDB hsa-miR-184 cancer laryngeal carcinoma, upregulated; control of the G1-S phase transition;regulate BTG2, a cell cycle gene 19546886 HMDD v2.0 hsa-miR-107 glioma MicroRNA-107 Inhibits U87 Glioma Stem Cells Growth and Invasion 23572380 HMDD v2.0 hsa-miR-638 lupus vulgaris miR-638: upregulation 18998140 HMDD v2.0 hsa-miR-599 multiple sclerosis relevant at the time of relapse 19617918 HMDD v2.0 hsa-miR-508-5p ovarian cancer up 24512620 dbDEMC v2.0 hsa-miR-451a erythropoiesis miR-451:a loss of miR-451, a small RNA important for erythropoiesis 20424607 HMDD v2.0 hsa-miR-429 breast cancer Two members of the miR-200 family (miR-200c and miR-429) were predominantly luminal. 21409395 HMDD v2.0 hsa-miR-302e pre-eclampsia Six miRNAs were more than 2-fold over-expressed in severe preeclampsia: let-7b, miRNA-302*, miRNA-104, miRNA-128a, miRNA-182* and miRNA-133b. 21309633 HMDD v2.0 hsa-miR-451a glioma MicroRNA miR-451 downregulates the PI3K/AKT pathway through CAB39 in human glioma. 22179124 HMDD v2.0 hsa-miR-375 head and neck cancer Low-Level Expression of miR-375 Correlates with Poor Outcome and Metastasis While Altering the Invasive Properties of Head and Neck Squamous Cell Carcinomas. 22234174 HMDD v2.0 hsa-miR-520h breast cancer Breast cancer resistance protein BCRP/ABCG2 regulatory microRNAs (hsa-miR-328; -519c and -520h) and their differential expression in stem-like ABCG2+ cancer cells. 21219875 HMDD v2.0 hsa-miR-198 hepatocellular carcinoma miR-198: up to five-fold down-regulated in hepatic tumors compared to normal liver parenchyma 19360909 HMDD v2.0 hsa-miR-582-5p lymphoma up 19846888 dbDEMC v2.0 hsa-miR-602 HBV+ hepatocellular carcinoma inhibit apoptosis|promote cell proliferation 20364114 OncomiRDB hsa-miR-297 colorectal cancer miR-297 modulates multidrug resistance in human colorectal carcinoma by down-regulating MRP-2. 22676135 HMDD v2.0 hsa-miR-650 colorectal cancer NPA 21352815 OncomiRDB hsa-miR-373-3p colon cancer up 24239208 dbDEMC v2.0 hsa-miR-199a-5p NPA NPA 21189327 OncomiRDB hsa-miR-637 lupus vulgaris miR-637: downregulation 18998140 HMDD v2.0 hsa-miR-221-3p colon cancer up 24239208 dbDEMC v2.0 hsa-miR-378b bladder carcinoma hsa-miR-29c, hsa-miR-200a, hsa-miR-378, hsa-miR-429, hsa-miR-200c and hsa-miR-141 were up-regulated, while hsa-miR-451 was down-regulated. 22886973 HMDD v2.0 hsa-miR-103b breast cancer The serum levels of miR-103 expression were significantly higher in the cancer patients than in the healthy control group (P<0.01). In the cancer patients, high miR-103 expression was significantly correlated to advanced clinical stage (P<0.05) and lymph node metastasis (P<0.05). 22588912 HMDD v2.0 hsa-miR-17-5p melanoma promote cell proliferation 21541354 OncomiRDB hsa-miR-448 hepatitis c miR-448: down-regulated 19360909 HMDD v2.0 hsa-miR-509-5p ovarian cancer up 24512620 dbDEMC v2.0 hsa-miR-320a atrophic muscular disorders dysregulation 17942673 HMDD v2.0 hsa-miR-107 glioma MicroRNA-107 inhibits glioma cell migration and invasion by modulating Notch2 expression 23299462 HMDD v2.0 hsa-miR-107 breast cancer miR-107 promotes tumor progression by targeting the let-7 microRNA in mice and humans. 21841313 HMDD v2.0 hsa-miR-199a-3p osteosarcoma decrease cell growth|decrease cell migration|block cell cycle G1/S transition 21666078 OncomiRDB hsa-miR-6165 NPA induce apoptosis 22558167 OncomiRDB hsa-miR-380-5p neuroblastoma block oncogene-induced senescence|promote tumor formation|reduce apoptosis 20871609 OncomiRDB hsa-miR-574-3p sarcoma up 25784290 dbDEMC v2.0 hsa-miR-137 schizophrenia Schizophrenia-associated genes CSMD1, C10orf26, CACNA1C and TCF4 are miR-137 targets. 22182936 HMDD v2.0 hsa-miR-133b non small cell lung cancer inhibit cell growth 22883469 OncomiRDB hsa-miR-622 colon cancer miR-622:In particular, miR-126, miR-142-3p, miR-155, miR-552, and miR-630 were all upregulated, whereas miR-146a, miR-152, miR-205, miR-365, miR-449, miR-518c, miR-584, miR-615, and miR-622 were downregulated after NGX6 transfection. 20859756 HMDD v2.0 hsa-miR-375 head and neck squamous cell carcinoma inhibit cell proliferation|induce apoptosis 21753766 OncomiRDB hsa-miR-375 lung cancer with neuroendocrine NPA 21856745 OncomiRDB hsa-miR-608 lupus vulgaris miR-608: upregulation 18998140 HMDD v2.0 hsa-miR-375 head and neck cancer down 19351747 dbDEMC v2.0 hsa-miR-206 breast cancer inhibit cell proliferation of ER¦Á+ cells 20388878 OncomiRDB hsa-miR-638 lupus nephritis miR-638:hsa-miR-371-5P, hsa-miR-423-5P, hsa-miR-638, hsa-miR-1224-3P and hsa-miR-663 that were differentially expressed in lupus nephritis across different racial groups and all specimen types tested 20485490 HMDD v2.0 hsa-miR-133b hypertrophy Down-regulation of miR-1/miR-133 contributes to re-expression of pacemaker channel genes HCN2 and HCN4 in hypertrophic heart. 18458081 HMDD v2.0 hsa-miR-375 esophageal cancer Epigenetic Silencing of MicroRNA-375 Regulates PDK1 Expression in Esophageal Cancer 21533613 HMDD v2.0 hsa-miR-198 acquired immunodeficiency syndrome miR-198: miR-198 inhibits HIV-1 gene expression and replication in monocytes 19148268 HMDD v2.0 hsa-miR-199a-5p NPA induce apoptosis|increase trichostatin A sensitivity 23085757 OncomiRDB hsa-miR-375 gastric cancer reduce cell viability|induce caspase-mediated apoptosis 20215506 OncomiRDB hsa-miR-657 lupus vulgaris miR-657: upregulation 18998140 HMDD v2.0 hsa-miR-198 schizophrenia SNP (rs1700) disease susceptibility 17849003 HMDD v2.0 hsa-miR-204-5p gastric cancer down 25167801 dbDEMC v2.0 hsa-miR-1286 hpv infection We found hypermethylation of miR-432, miR-1286, miR-641, miR-1290, miR-1287 and miR-95 may have some relationship with HPV infection in cervical cell lines. 23732000 HMDD v2.0 hsa-miR-548d-3p NPA NPA 19486885 OncomiRDB hsa-miR-20a-5p colon cancer up 24239208 dbDEMC v2.0 hsa-miR-451a precursor b-cell lymphoblastic leukemia-lymphoma miR-451: down-regulated 19206004 HMDD v2.0 hsa-miR-133b myocardial infarction downregulated 20029200 HMDD v2.0 hsa-miR-603 pancreatic cancer altered expression 22114139 HMDD v2.0 hsa-miR-206 endometrioid carcinoma Expression of the tumor suppressor miR-206 is associated with cellular proliferative inhibition and impairs invasion in ER¦Á-positive endometrioid adenocarcinoma. 21983130 HMDD v2.0 hsa-miR-615-5p heptocellular carcinoma inhibit cell growth|inhibit cell migration 22819824 OncomiRDB hsa-miR-378i prostate cancer MiR-375, miR-378*, and miR-141 were significantly over-expressed in serum from CRPC patients compared with serum from low-risk localized patients, while miR-409-3p was significantly under-expressed. In prostate primary tumor samples, miR-375 and miR-141 also had significantly higher expression levels compared with those in normal prostate tissue. 22887127 HMDD v2.0 hsa-miR-107 hepatocellular carcinoma This miRNA was down-regulated in HepG2 cells treated with BJA32515. 22027761 HMDD v2.0 hsa-miR-526a heart failure downregulated 17606841 HMDD v2.0 hsa-miR-544b gastric cancer Oncogenic miR-544 is an Important Molecular Target in Gastric Cancer. 22934698 HMDD v2.0 hsa-miR-1245a breast cancer Upregulation of miR-1245 by c-myc targets BRCA2 and impairs DNA repair. 22158906 HMDD v2.0 hsa-miR-375 thyroid carcinoma MTC (medullary thyroid carcinomas) and CCH (C-cell hyperplasia) were both characterized by a significant overexpression of the miRNA. 22550943 HMDD v2.0 hsa-miR-1305 glioblastoma Significantly deregulated miRNAs were miR-3163 (fold change 2.0, p = 0.05), miR-539 (fold change 0.5, p = 0.001), miR-1305 (fold change 0.5, p = 0.05), miR-1260 (fold change 0.5, p = 0.03) and let-7a (fold change 0.3, p = 0.02) after temozolomide treatment. 22074483 HMDD v2.0 hsa-miR-614 multiple sclerosis Six plasma miRNA (miR-614, miR-572, miR-648, miR-1826, miR-422a and miR-22) that were significantly up-regulated and one plasma miRNA (miR-1979) that was significantly down-regulated in MS individuals. 22231906 HMDD v2.0 hsa-miR-650 melanoma miR-142-3p, miR-486, miR-214, miR-218, miR-362, miR-650 and miR-31, were significantly correlated with acral as compared to non-acral melanomas (p < 0.04). 21543894 HMDD v2.0 hsa-miR-429 cancer miR-429: miR-200 family:inhibit the initiating step of metastasis, epithelial-mesenchymal transition (EMT), by maintaining the epithelial phenotype through direct targeting of transcriptional repressors of E-cadherin, ZEB1 and ZEB2 19182522 HMDD v2.0 hsa-miR-429 gastric cancer reduce cell viability|inhibit cell proliferation|inhibit cell attachment 21684154 OncomiRDB hsa-miR-107 B-cell chronic lymphocytic leukemia regulation of PLAG1 by miR-181a, miR-181b, miR-107, and miR-424 19692702 HMDD v2.0 hsa-miR-650 B-cell chronic lymphocytic leukemia MicroRNA-650 expression is influenced by immunoglobulin gene rearrangement and affects the biology of chronic lymphocytic leukemia. 22234685 HMDD v2.0 hsa-miR-378f bladder carcinoma hsa-miR-29c, hsa-miR-200a, hsa-miR-378, hsa-miR-429, hsa-miR-200c and hsa-miR-141 were up-regulated, while hsa-miR-451 was down-regulated. 22886973 HMDD v2.0 hsa-miR-378c renal cell carcinoma The level of miR-378 was significantly increased in serum of ccRCC patients. 22542158 HMDD v2.0 hsa-miR-451a pancreatic cancer The expression of let-7c, let-7f, and miR-200c were significantly reduced in most patients whereas the expression of miR-486-5p and miR-451 were significantly elevated in all pancreas cancer patients. 22929886 HMDD v2.0 hsa-miR-206 laryngeal cancer downregulated by 5 multiple 20806854 HMDD v2.0 hsa-miR-516a-3p scirrhous gastric cancer inhibit tumorigenicity 21169410 OncomiRDB hsa-miR-4732-5p colon cancer up 24239208 dbDEMC v2.0 hsa-miR-107 gastric cancer In the analysis by real-time PCR-based miRNA arrays using pooled RNA samples from five gastric cancer patients, expression of miR-107, miR-21, miR-196a, miR-26b, miR-9, miR-142-3p, miR-30b, miR-150, miR-191 and miR-17 was found to be upregulation.miR-107 expression showed significant association with depth of tumor invasion, lymph node metastasis and stage. In Kaplan-Meier survival curve analysis, overall survival rates (OS) and disease-free survival rates (DFS) of patients with high miR-107 expression were significantly worse than those of patients with low miR-107 expression. In the Cox multivariate analysis, it was shown that miR-107 expression in gastric cancer tissues was an independent prognostic factor for OS and DFS. Significant inverse correlations were demonstrated between miR-107 and DICER1 mRNA. Our results indicate that miR-107 may be useful as an effective biomarker for prediction of a poor prognosis in gastric cancer patients. 22407237 HMDD v2.0 hsa-miR-184 squamous cell carcinoma The authors found that, compared with the rs8126 TT (a SNP of miR-184 Binding Site in TNFAIP2) genotype, the variant C allele were associated with increased SCCHN risk in an allele-dose response manner (adjusted odds ratio=1.48 and 95% confidence interval=1.06-2.05 for CC, respectively; P(trend)=0.009). 21934093 HMDD v2.0 hsa-miR-451a pancreatic cancer Highly down-regulated in PDAC compared with normal ductal 21953293 HMDD v2.0 hsa-miR-422a laryngeal cancer downregulated by 5 multiple 20806854 HMDD v2.0 hsa-miR-625-3p colon cancer down 24239208 dbDEMC v2.0 hsa-miR-199a-5p hepatocellular carcinoma inhibit cell proliferation|inhibit autophagy 22713463 OncomiRDB hsa-miR-2110 colorectal cancer differentially expressed 22850566 HMDD v2.0 hsa-miR-107 pituitary adenoma inhibit cell proliferation 22811466 OncomiRDB hsa-miR-137 colorectal cancer inhibit cell proliferation|inhibit cell invasion|inhibit metastasis 23201162 OncomiRDB hsa-miR-133b atherosclerosis deregulated 21817153 HMDD v2.0 hsa-miR-617 esophageal cancer Thirteen miRNAs (miR-199a-5p, miR-302f, miR-320a, miR-342-3p, miR-425, miR-455-3p, miR-486-3p, miR-519c-5p, miR-548d-5p, miR-617, miR-758, miR-766, miR-1286) were deregulated after 24- and/or 72-h treatment by Chemotherapy. 21743970 HMDD v2.0 hsa-miR-544b glioma Downregulation of miR-544 in tissue, but not in serum, is a novel biomarker of malignant transformation in glioma 23205130 HMDD v2.0 hsa-miR-1273a adenoviridae infections miR-1273:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control 20634878 HMDD v2.0 hsa-miR-184 cancer down-regulated 19676045 HMDD v2.0 hsa-miR-1827 small cell carcinoma Genetic Variation in an miRNA-1827 Binding Site in MYCL1 Alters Susceptibility to Small-Cell Lung Cancer. The rs3134615T allele was associated with a significantly increased risk of SCLC, with the OR for carrying the GT or TT genotype being 2.08 (95% confidence interval, 1.39-3.21; P = 0.0004) compared with the GG genotype. 21676885 HMDD v2.0 hsa-miR-206 ER¦Á+ endometrioid adenocarcinoma inhibit ER¦Á-dependent cell proliferation|reduce cell invasion|induce cell cycle arrest 21983130 OncomiRDB hsa-miR-518b esophageal squamous cell carcinoma inhibit cell proliferation|induce apoptosis|inhibit cell invasion 22958893 OncomiRDB hsa-miR-125a-5p lung cancer inhibit cell migration|inhibit cell invasion 19702827 OncomiRDB hsa-miR-375 maxillary sinus squamous cell carcinoma inhibit cell proliferation|inhibit cell invasion 21922130 OncomiRDB hsa-miR-429 ovarian cancer Overexpression of miR-429 induces mesenchymal-to-epithelial transition (MET) in metastatic ovarian cancer cells. 21277012 HMDD v2.0 hsa-miR-375 breast cancer reduce tamoxifen resistance|inhibit epithelial-mesenchymal transition 22508479 OncomiRDB hsa-miR-449a ovarian cancer The expressions of miR-449a/b, miR-34b and miR-34c were 19-fold to 21-fold elevated after p53 activation by genotoxic agent adriamycin. 22340095 HMDD v2.0 hsa-miR-451a pulmonary tuberculosis hsa-miR-451: differently expressed in the samples from study participants with active tuberculosis (TB) versus latent tuberculosis infection (LTBI). 22003408 HMDD v2.0 hsa-miR-137 glioblastoma miR-137 is frequently down-regulated in glioblastoma and is a negative regulator of Cox-2. 22406049 HMDD v2.0 hsa-miR-346 follicular thyroid carcinoma promote cell proliferation 16822819 OncomiRDB hsa-miR-137 colorectal cancer inhibit cell proliferation 20682795 OncomiRDB hsa-miR-378d renal cell carcinoma The level of miR-378 was significantly increased in serum of ccRCC patients. 22542158 HMDD v2.0 hsa-miR-206 gastric cancer Downregulation of microRNA-206 is a potent prognostic marker for patients with gastric cancer. 23751352 HMDD v2.0 hsa-miR-559 NPA NPA 19486885 OncomiRDB hsa-miR-378d basal cell carcinoma downregulated in the tumor center 22540308 HMDD v2.0 hsa-miR-206 cancer The inhibition of cancer cell migration and foci formation by miR-206 strongly suggests that miR-206 may function as a novel tumor suppressor. 19723635 HMDD v2.0 hsa-miR-630 pancreatic cancer Upregulation of miR-150* and miR-630 Induces Apoptosis in Pancreatic Cancer Cells by Targeting IGF-1R. 23675407 HMDD v2.0 hsa-miR-1471 breast cancer The miRNA is down-regulated in whole blood of breast cancer patients 22242178 HMDD v2.0 hsa-miR-583 lupus vulgaris miR-583: upregulation 18998140 HMDD v2.0 hsa-miR-663a nasopharyngeal cancer MiR-663, a microRNA targeting p21(WAF1/CIP1), promotes the proliferation and tumorigenesis of nasopharyngeal carcinoma. 22249270 HMDD v2.0 hsa-miR-765 anxiety disorders Allele variants in functional MicroRNA target sites of the neurotrophin-3 receptor gene (NTRK3) as susceptibility factors for anxiety disorders. 19370765 HMDD v2.0 hsa-miR-206 cervical cancer induce apoptosis|inhibit cell migration|inhibit focus formation 19723635 OncomiRDB hsa-miR-296-5p gastric cancer promote cell growth|inhibit apoptosis|change cell cycle distribution 23353818 OncomiRDB hsa-miR-421 gastric cancer miR-421: overexpressed 19175831 HMDD v2.0 hsa-miR-451a renal cell carcinoma Down-regulated in the blook serum of patients with renal cell carcinoma compared to healthy controls. 22440013 HMDD v2.0 hsa-miR-520b breast cancer increase complement-dependent cytotoxicity sensitivity 20574151 OncomiRDB hsa-miR-378f basal cell carcinoma downregulated in the tumor center 22540308 HMDD v2.0 hsa-miR-375 hepatocellular carcinoma MicroRNA-375 targets Hippo-signaling effector YAP in liver cancer and inhibits tumor properties 20226166 HMDD v2.0 hsa-miR-548c-3p gastric cancer down 25167801 dbDEMC v2.0 hsa-miR-574-3p gastric cancer inhibit cell proliferation|inhibit cell migration|inhibit cell invasion 22683180 OncomiRDB hsa-miR-103b lung cancer Here we report that miR-30b, miR-30c, miR-221 and miR-222 are modulated by both epidermal growth factor (EGF) and MET receptors, whereas miR-103 and miR-203 are controlled only by MET. We showed that these miRNAs have important roles in gefitinib-induced apoptosis and epithelial-mesenchymal transition of NSCLC cells in vitro and in vivo by inhibiting the expression of the genes encoding BCL2-like 11 (BIM), apoptotic peptidase activating factor 1 (APAF-1), protein kinase C ? (PKC-?) and sarcoma viral oncogene homolog (SRC). 22157681 HMDD v2.0 hsa-miR-34c-5p lung cancer up 22331473 dbDEMC v2.0 hsa-miR-17-5p breast cancer promote cell invasion|promote cell migration 20505989 OncomiRDB hsa-miR-544a glioma Downregulation of miR-544 in tissue, but not in serum, is a novel biomarker of malignant transformation in glioma 23205130 HMDD v2.0 hsa-miR-139-5p adrenocortical carcinoma down 20484036 dbDEMC v2.0 hsa-miR-375 adrenocortical carcinoma ACCs (adrenocortical carcinomas) exhibited significantly lower levels of miR-139-3p (up to 8.49-fold, p<0.001), miR-675 (up to 23.25-fold, p<0.001) and miR-335 (up to 5.25-fold, p<0.001). 21471143 HMDD v2.0 hsa-miR-206 breast cancer mir-206 upregulated in breast cancer (Iorio et al., 2005). 17028596 HMDD v2.0 hsa-miR-206 musculoskeletal abnormalities Studies to evaluate the role of miRNAs in muscular dystrophy showed a dramatic increase in miR-206 expression in the diaphragm of the mdx mouse. 17917533 HMDD v2.0 hsa-miR-181b-5p colon cancer up 24239208 dbDEMC v2.0 hsa-miR-147a pulmonary tuberculosis Overexpression 22900099 HMDD v2.0 hsa-miR-3663-3p colon cancer up 24239208 dbDEMC v2.0 hsa-miR-107 atrophic muscular disorders dysregulation 17942673 HMDD v2.0 hsa-miR-375 gastric cancer MiR-375:MiR-375 frequently downregulated in gastric cancer inhibits cell proliferation by targeting JAK2 20548334 HMDD v2.0 hsa-miR-663a autistic disorder miR-663: upregulated 19360674 HMDD v2.0 hsa-miR-107 head and neck squamous cell carcinoma reduce clonogenic survival|inhibit cell invasion|inhibit cell migration|reduce the cancer-initiating cell population|inhibit tumor growth 22491216 OncomiRDB hsa-miR-621 melanoma miR-621:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients 20529253 HMDD v2.0 hsa-miR-198 prostate cancer Livin expression may be regulated by miR-198 in human prostate cancer cell lines 23069480 HMDD v2.0 hsa-miR-622 colon cancer down 19922656 dbDEMC v2.0 hsa-miR-4257 breast cancer The miRNA is up-regulated in whole blood of breast cancer patients 22242178 HMDD v2.0 hsa-miR-520e breast cancer increase complement-dependent cytotoxicity sensitivity 20574151 OncomiRDB hsa-miR-133b pheochromocytoma up 23660872 dbDEMC v2.0 hsa-miR-137 neuroblastoma increase apoptosis|inhibit cell migration|inhibit cell proliferation 23400681 OncomiRDB hsa-miR-133b pre-eclampsia Six miRNAs were more than 2-fold over-expressed in severe preeclampsia: let-7b, miRNA-302*, miRNA-104, miRNA-128a, miRNA-182* and miRNA-133b. 21309633 HMDD v2.0 hsa-miR-650 adenoviridae infections miR-650:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control 20634878 HMDD v2.0 hsa-miR-378e bladder carcinoma miR-10b, 19a, 126, 145, 221, 296-5p and 378 were significantly down-regulated in bladder carcinoma compared to adjacent normal urothelium. 22704449 HMDD v2.0 hsa-miR-107 heart failure miR-107: downregulated 20484156 HMDD v2.0 hsa-miR-198 lupus nephritis Intra-renal expression of miR-638, miR-198 and miR-146a are differentially expressed between LN patients and normal controls. Furthermore, the degree of change in glomerular miR-146a and tubulointerstitial miR-638 expression correlated with clinical disease severity. 22295894 HMDD v2.0 hsa-miR-449a bladder carcinoma inhibit cell growth|induce cell cycle G1 arrest|reduce tumor growth 22266187 OncomiRDB hsa-miR-137 squamous cell carcinoma miR-137:MicroRNA-137 promoter methylation in oral rinses from patients with squamous cell carcinoma of the head and neck is associated with gender and body mass index 20197299 HMDD v2.0 hsa-miR-637 hepatocellular carcinoma Primate-specific miRNA-637 inhibits tumorigenesis in hepatocellular carcinoma by disrupting stat3 signaling. 21809363 HMDD v2.0 hsa-miR-206 hypertrophy miR-206:have a profound influence on multiple myopathies 20619221 HMDD v2.0 hsa-miR-184 tongue squamous cell carcinoma promote cell proliferation|inhibit apoptosis 18451220 OncomiRDB hsa-miR-217 melanoma miR-217:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients 20529253 HMDD v2.0 hsa-miR-193a-3p breast cancer regulate EGFR signaling|inhibit cell cycle progression|inhibit cell proliferation 22333974 OncomiRDB hsa-miR-449a prostate cancer miR-449a targets HDAC-1 and induces growth arrest in prostate cancer. 19252524 HMDD v2.0 hsa-miR-137 melanoma miR-137 Inhibits the Invasion of Melanoma Cells through Downregulation of Multiple Oncogenic Target Genes 23151846 HMDD v2.0 hsa-miR-608 colorectal cancer rs4919510 in hsa-miR-608 is associated with outcome but not risk of colorectal cancer. 22606253 HMDD v2.0 hsa-miR-650 gastric cancer promote tumorigenesis|promote cell proliferation 20381459 OncomiRDB hsa-miR-375 melanoma Ectopic expression of miR-375 inhibited melanoma cell proliferation, invasion, and cell motility, and induced cell shape changes, strongly suggesting that miR-375 may have an important function in the development and progression of human melanomas. 21723283 HMDD v2.0 hsa-miR-206 muscular dystrophies The expression of miR-206 is increased in muscular dystrophy. 22129894 HMDD v2.0 hsa-miR-302f gastric cancer Real-time RT-PCR analysis demonstrated an increase in mir-21 and mir-302 expression level in CSCs(cancer stem cells), relative to cancer cells, whereas let-7a expression level was decreased in CSC in comparison with cancer cells. mir-372, mir-373 and mir-520c-5p were markedly increased in cancer cells in comparison with CSCs. 22374783 HMDD v2.0 hsa-miR-615-5p lung cancer up 22331473 dbDEMC v2.0 hsa-miR-1302 male infertility Two SNPs from two genes (rs6631 of CGA and rs2303846 of CPEB1)(binding sites of miR-1302) were found to be associated with idiopathic male infertility. Functionally, the substitution of A by T in rs6631 results in decreased binding affinity of miR-1302 and overexpression of CGA in vitro. 21601192 HMDD v2.0 hsa-miR-320a heart failure upregulated 17606841 HMDD v2.0 hsa-miR-206 rhabdomyosarcoma miR-1 was barely detectable in primary RMS 19620785 HMDD v2.0 hsa-miR-206 mesothelioma down 23828229 dbDEMC v2.0 hsa-miR-17-5p neuroblastoma promote cell growth|promote therapy resistance 18493594 OncomiRDB hsa-miR-198 hepatocellular carcinoma miR-198 inhibits migration and invasion of hepatocellular carcinoma cells by targeting the HGF/c-MET pathway. 21658389 HMDD v2.0 hsa-miR-657 hepatocellular carcinoma increase cell proliferation|increase colony formation|promote tumor development 23175432 OncomiRDB hsa-miR-429 azoospermia Genome-wide microRNA expression profiling in idiopathic non-obstructive azoospermia: significant up-regulation of miR-141, miR-429 and miR-7-1-3p 23559187 HMDD v2.0 hsa-miR-520h endometriosis A microRNA-520 mirSNP at the MMP2 gene influences susceptibility to endometriosis in Chinese women 23364396 HMDD v2.0 hsa-miR-320a heart failure significantly increased serum level 22120965 HMDD v2.0 hsa-miR-320a prostate cancer MicroRNA-320 suppresses the stem cell-like characteristics of prostate cancer cells by downregulating the Wnt/beta-catenin signaling pathway 23188675 HMDD v2.0 hsa-miR-378b basal cell carcinoma downregulated in the tumor center 22540308 HMDD v2.0 hsa-miR-449a NPA induce cell cycle G1 arrest 19833767 OncomiRDB hsa-miR-1246 down syndrome p53 downregulates Down syndrome-associated DYRK1A through miR-1246. 21637297 HMDD v2.0 hsa-miR-1202 hepatocellular carcinoma recurence related 21298008 HMDD v2.0 hsa-miR-137 lung cancer miR-137 inhibits the proliferation of lung cancer cells by targeting Cdc42 and Cdk6 23178712 HMDD v2.0 hsa-miR-375 prostate cancer up 21400514 dbDEMC v2.0 hsa-miR-633 endometrial cancer Decreased expression after Progesterone Treatment. 22543862 HMDD v2.0 hsa-miR-125a-5p gastric cancer inhibit cell proliferation 21220473 OncomiRDB hsa-miR-375 Er¦Á+ breast cancer promote cell proliferation 20978187 OncomiRDB hsa-miR-384 laryngeal cancer downregulated by 5 multiple 20806854 HMDD v2.0 hsa-miR-133b colorectal cancer High expression of miR-185 and low expression of miR-133b were correlated with poor survival (p=0.001 and 0.028, respectively) and metastasis (p=0.007 and 0.036, respectively) in colorectal cancer. 21573504 HMDD v2.0 hsa-miR-429 breast cancer downregulated in human BCSCs 19665978 HMDD v2.0 hsa-miR-944 bladder carcinoma Three miRNAs were associated with both response (to chemotherapy) and survival (886-3p, 923, 944). 22954303 HMDD v2.0 hsa-miR-155-5p brain cancer down 24519663 dbDEMC v2.0 hsa-miR-526a hepatocellular carcinoma This miRNA was down-regulated in HepG2 cells treated with BJA32515. 22027761 HMDD v2.0 hsa-miR-663a cancer Expression of human endogenous retrovirus-K coincides with that of micro-RNA-663 and -638 in germ-cell tumor cells 23155245 HMDD v2.0 hsa-miR-320a ischemia MicroRNA 320a functions as a novel endogenous modulator of aquaporins 1 and 4 as well as a potential therapeutic target in cerebral ischemia 20628061 HMDD v2.0 hsa-miR-378d prostate cancer MiR-375, miR-378*, and miR-141 were significantly over-expressed in serum from CRPC patients compared with serum from low-risk localized patients, while miR-409-3p was significantly under-expressed. In prostate primary tumor samples, miR-375 and miR-141 also had significantly higher expression levels compared with those in normal prostate tissue. 22887127 HMDD v2.0 hsa-miR-30c-2-3p kidney cancer down 24189146 dbDEMC v2.0 hsa-miR-133b gastric cancer inhibit cell proliferation|inhibti colony formation 23296701 OncomiRDB hsa-miR-378e renal cell carcinoma The level of miR-378 was significantly increased in serum of ccRCC patients. 22542158 HMDD v2.0 hsa-miR-933 melanoma The downregulation of this miRNA was associated with selective genomic loss in SSM cell lines and primary tumors. 22551973 HMDD v2.0 hsa-miR-1290 renal cell carcinoma Up-regulation in serum and tissue of RCC patients: miR-7-1*, miR-93, miR-106b*, miR-210, miR-320b, miR-1233 and miR-1290 21984948 HMDD v2.0 hsa-miR-142-5p lung cancer inhibit cell growth 19228723 OncomiRDB hsa-miR-137 schizophrenia Candidate schizophrenia gene ZNF804A is a target for hsa-miR-137. 22883350 HMDD v2.0 hsa-miR-378c basal cell carcinoma downregulated in the tumor center 22540308 HMDD v2.0 hsa-miR-199a-3p NPA NPA 21189327 OncomiRDB hsa-miR-346 brain cancer down 18973228 dbDEMC v2.0 hsa-miR-326 esophageal cancer down 21128279 dbDEMC v2.0 hsa-miR-526a gastric cancer A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemoresistance 22112324 HMDD v2.0 hsa-miR-17-5p colon cancer up 24239208 dbDEMC v2.0 hsa-miR-1297 lung cancer inhibit cell proliferation 23071539 OncomiRDB hsa-miR-184 glioblastoma Expression of miR-128a, -504, -124a, and -184 each negatively correlated with the expression of mesenchymal markers in GBM. 22844109 HMDD v2.0 hsa-miR-582-5p bladder carcinoma reduce cell proliferation|reduce cell invasion|reduce tumor growth|reduce metastasis 23295946 OncomiRDB hsa-miR-326 glioblastoma Interactions of miR-323/miR-326/miR-329 and miR-130a/miR-155/miR-210 as prognostic indicators for clinical outcome of glioblastoma patients 23302469 HMDD v2.0 hsa-miR-375 prostate cancer Circulating miR-141 and miR-375 have association with metastatic prostate cancer. 22240788 HMDD v2.0 hsa-miR-103b colorectal cancer miR-103/107 Promote Metastasis of Colorectal Cancer by Targeting the Metastasis Suppressors DAPK and KLF4. 22593189 HMDD v2.0 hsa-miR-646 colorectal cancer deleted 21128281 HMDD v2.0 hsa-miR-206 glioblastoma altered expression after Polyunsaturated fatty acids (PUFAs) treatment 21961478 HMDD v2.0 hsa-miR-638 breast cancer Treatment with E2, BPA and DDT decreased (p<0.05) miR-21 expression. Several members of the let-7 family (let-7a, let-7b, let-7c, let-7d, let-7e and let-7f), were downregulated (p<0.05) by all three treatments.and miR-15b (p<0.005) and miR-27b (p<0.01) were also downregulated by the three treatments.upregulation of miR-638 (P<0.005), miR-663 (P<0.005), and miR-1915 (P<0.005) was observed after treatment of MCF7 cells with E2, BPA or DDT 22403704 HMDD v2.0 hsa-miR-577 gastric cancer A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemosensitivity 22112324 HMDD v2.0 hsa-miR-648 multiple sclerosis Six plasma miRNA (miR-614, miR-572, miR-648, miR-1826, miR-422a and miR-22) that were significantly up-regulated and one plasma miRNA (miR-1979) that was significantly down-regulated in MS individuals. 22231906 HMDD v2.0 hsa-miR-375 diabetes mellitus For instance, miR-375 was shown to directly regulate insulin secretion from pancreatic islet cells. Overexpression of miR-375 led to an enhanced inhibition of insulin exocytosis, whereas anti-sense to miR-375 enhanced insulin secretion by blocking the effects of the miRNA. 17965831 HMDD v2.0 hsa-miR-107 type 2 diabetes mellitus miR-107: a Toll-like receptor-regulated miRNA dysregulated in obesity and type II diabetes. 22645244 HMDD v2.0 hsa-miR-650 hepatocellular carcinoma Upregulation of miR-650 is correlated with down-regulation of ING4 and progression of hepatocellular carcinoma. 22767438 HMDD v2.0 hsa-miR-137 colorectal cancer Overexpression of paxillin induced by miR-137 suppression promotes tumor progression and metastasis in colorectal cancer 23275153 HMDD v2.0 hsa-miR-133b esophageal squamous cell carcinoma NPA 21351259 OncomiRDB hsa-miR-137 pheochromocytoma up 23660872 dbDEMC v2.0 hsa-miR-1290 hepatocellular carcinoma hsa-miR-1290 was down-regulated in HepG2 cells after 5 hours of culture with grape seed proanthocyanidin extract. 21998738 HMDD v2.0 hsa-miR-326 glioma Down-regulation of miR-326 may have potential value for predicting clinical outcomes in glioma patients with high pathological grades, suggesting that miR-326 is an important candidate tumor suppressor, and its down-regulated expression may contribute to glioma progression 23292865 HMDD v2.0 hsa-miR-612 hepatocellular carcinoma miR-612 suppresses the invasive-metastatic cascade in hepatocellular carcinoma 23478189 HMDD v2.0 hsa-miR-2110 hepatocellular carcinoma hsa-miR-2110 was down-regulated in HepG2 cells after 5 hours of culture with grape seed proanthocyanidin extract. 21998738 HMDD v2.0 hsa-miR-106b-5p colon cancer up 24239208 dbDEMC v2.0 hsa-miR-375 colorectal cancer differentially expressed 22850566 HMDD v2.0 hsa-miR-30a-5p lung cancer down 23029380 dbDEMC v2.0 hsa-miR-564 bcr-abl positive chronic myelogenous leukemia Downregulation of mir-31, mir-155, and mir-564 in chronic myeloid leukemia cells. 22511990 HMDD v2.0 hsa-miR-375 laryngeal cancer downregulated by 5 multiple 20806854 HMDD v2.0 hsa-miR-520b heart failure downregulated 17606841 HMDD v2.0 hsa-miR-571 liver cirrhosis significant alterations in serum levels of miR-513-3p, miR-571 and miR-652. Up-regulation of miR-571 in serum reflected a concordant regulation in cirrhotic liver tissue. 22412969 HMDD v2.0 hsa-miR-498 perennial allergic rhinitis down-regulated 22185732 HMDD v2.0 hsa-miR-663a adult T cell leukemia induced 21865341 HMDD v2.0 hsa-miR-637 osteoporosis miR-637 suppressed the growth of hMSCs and induced S-phase arrest. Expression of miR-637 was increased during adipocyte differentiation (AD) whereas it was decreased during osteoblast differentiation (OS), which suggests that miR-637 could act as a mediator of adipo-osteogenic differentiation. Disruption of this differentiation balance leads to various bone-related metabolic diseases, including osteoporosis. Therefore, miR-637 could contributes to osteoporosis. 21880893 HMDD v2.0 hsa-miR-331-3p prostate cancer inhibit cell proliferation 22908221 OncomiRDB hsa-miR-421 neuroblastoma change cell cycle S-phase checkpoint|increase radiation sensitivty 20080624 OncomiRDB hsa-miR-1297 laryngeal squamous cell carcinoma promote cell proliferation|promote cell migration|promote tumorgenesis 22995297 OncomiRDB hsa-miR-498 colon cancer miR-498: correlated with the probability of recurrence-free survival 18676867 HMDD v2.0 hsa-miR-375 lung cancer miR-375 is activated by ASH1 and inhibits YAP1 in a lineage dependent manner in lung cancer. 21856745 HMDD v2.0 hsa-miR-326 adult T cell leukemia induced 21865341 HMDD v2.0 hsa-miR-331-3p gastric cancer block cell cycle G1/S transition|reduce colony formation|reduce cell growth 20510161 OncomiRDB hsa-miR-567 colorectal cancer hsa-miR-1273c, hsa-miR-1303 and hsa-miR-567, with frequent and sometimes bi-allelic mutations in MSI tumors. 22348132 HMDD v2.0 hsa-miR-320a breast cancer Expression of the Pten-miR-320-Ets2-regulated secretome distinguished human normal breast stroma from tumour stroma and robustly correlated with recurrence in breast cancer patients. This work reveals miR-320 as a critical component of the Pten tumour-suppressor axis that acts in stromal fibroblasts to reprogramme the tumour microenvironment and curtail tumour progression. 22179046 HMDD v2.0 hsa-miR-575 lupus vulgaris miR-575: upregulation 18998140 HMDD v2.0 hsa-miR-520h pancreatic cancer miR-520h:miR-520h downregulates ABCG2 in pancreatic cancer cells to inhibit migration, invasion, and side populations 20628378 HMDD v2.0 hsa-miR-422a multiple sclerosis Six plasma miRNA (miR-614, miR-572, miR-648, miR-1826, miR-422a and miR-22) that were significantly up-regulated and one plasma miRNA (miR-1979) that was significantly down-regulated in MS individuals. 22231906 HMDD v2.0 hsa-miR-509-3p ovarian cancer up 24512620 dbDEMC v2.0 hsa-miR-137 brain cancer down 24519663 dbDEMC v2.0 hsa-miR-3175 colon cancer up 24239208 dbDEMC v2.0 hsa-miR-133b heart failure MicroRNA-1 and -133 Increase Arrhythmogenesis in Heart Failure by Dissociating Phosphatase Activity from RyR2 Complex. 22163007 HMDD v2.0 hsa-miR-661 breast cancer promote cell invasion|promote epithelial-mesenchymal transition 20543867 OncomiRDB hsa-miR-378g basal cell carcinoma downregulated in the tumor center 22540308 HMDD v2.0 hsa-miR-378h bladder carcinoma miR-10b, 19a, 126, 145, 221, 296-5p and 378 were significantly down-regulated in bladder carcinoma compared to adjacent normal urothelium. 22704449 HMDD v2.0 hsa-miR-1290 breast cancer MiR-1290 and its potential targets are associated with characteristics of estrogen receptor alpha-positive breast cancer 23183268 HMDD v2.0 hsa-miR-107 chronic kidney failure Differential expression was detected for miR-142-3p, miR-204, miR-107 and miR-211 (p < 0.001) and miR-32 (p < 0.05). 21794090 HMDD v2.0 hsa-miR-551a gastric cancer MiR-495 and miR-551a inhibit the migration and invasion of human gastric cancer cells by directly interacting with PRL-3. 22469786 HMDD v2.0 hsa-miR-324-3p brain cancer down 18973228 dbDEMC v2.0 hsa-miR-640 pulmonary tuberculosis hsa-miR-640: differently expressed in the samples from study participants with active tuberculosis (TB) versus latent tuberculosis infection (LTBI). 22003408 HMDD v2.0 hsa-miR-206 breast cancer down 22438871 dbDEMC v2.0 hsa-miR-326 multiple sclerosis The expression of miRNA-326 in blood cells has been reported to increase during relapses. 21151203 HMDD v2.0 hsa-miR-640 B-cell chronic lymphocytic leukemia correlated with assessment of biological impact on Chronic Lymphocytic Leukemia 19717645 HMDD v2.0 hsa-miR-320d interstitial cystitis demonstrate a direct correlation between miR-449b, miR-500, miR-328, and miR-320 and a down-regulation of NK1R mRNA and/or protein levels 20008142 HMDD v2.0 hsa-miR-325 dyspepsia Genetic polymorphism ( rs5981521 (C>T)) of pri-microRNA 325, targeting SLC6A4 3'-UTR, is closely associated with the risk of functional dyspepsia in Japan. 22438098 HMDD v2.0 hsa-miR-217 hepatocellular carcinoma MiR-216a/217-induced epithelial-mesenchymal transition targets PTEN and SMAD7 to promote drug resistance and recurrence of liver cancer 23471579 HMDD v2.0 hsa-miR-137 melanoma miR-137 under expression was significantly associated with melanomas with the KRAS-variant. 21543894 HMDD v2.0 hsa-miR-638 lupus nephritis Intra-renal expression of miR-638, miR-198 and miR-146a are differentially expressed between LN patients and normal controls. Furthermore, the degree of change in glomerular miR-146a and tubulointerstitial miR-638 expression correlated with clinical disease severity. 22295894 HMDD v2.0 hsa-miR-217 pancreatic cancer altered expression 21463235 HMDD v2.0 hsa-miR-375 squamous cell carcinoma underexpression 20145181 HMDD v2.0 hsa-miR-378b prostate cancer MiR-375, miR-378*, and miR-141 were significantly over-expressed in serum from CRPC patients compared with serum from low-risk localized patients, while miR-409-3p was significantly under-expressed. In prostate primary tumor samples, miR-375 and miR-141 also had significantly higher expression levels compared with those in normal prostate tissue. 22887127 HMDD v2.0 hsa-miR-1231 hepatocellular carcinoma A miR-1231 binding site polymorphism (rs17875871) in the 3'UTR of IFNAR1 is associated with hepatocellular carcinoma susceptibility. 22824466 HMDD v2.0 hsa-miR-512-5p lung cancer up 22331473 dbDEMC v2.0 hsa-miR-429 gastric cancer miR-200bc/429 cluster modulates multidrug resistance of human cancer cell lines by targeting BCL2 and XIAP. 21993663 HMDD v2.0 hsa-miR-512-5p gastric cancer induce apoptosis 19503096 OncomiRDB hsa-miR-544a gastric cancer Oncogenic miR-544 is an Important Molecular Target in Gastric Cancer. 22934698 HMDD v2.0 hsa-miR-183-3p colon cancer up 24239208 dbDEMC v2.0 hsa-miR-509-3p renal cell carcinoma inhibit cell proliferation|induce apoptosis|inhibit cell migration 22369946 OncomiRDB hsa-miR-184 keratoconus Mutation Altering the miR-184 Seed Region Causes Familial Keratoconus with Cataract. 21996275 HMDD v2.0 hsa-miR-320e breast cancer Expression of the Pten-miR-320-Ets2-regulated secretome distinguished human normal breast stroma from tumour stroma and robustly correlated with recurrence in breast cancer patients. This work reveals miR-320 as a critical component of the Pten tumour-suppressor axis that acts in stromal fibroblasts to reprogramme the tumour microenvironment and curtail tumour progression. 22179046 HMDD v2.0 hsa-miR-137 intellectual disability The patients displayed a significantly decreased expression of both precursor and mature miR-137 levels, as well as significantly increased expression of the validated downstream targets microphthalmia-associated transcription factor (MITF) and Enhancer of Zeste, Drosophila, Homologue 2 (EZH2), and the newly identified target Kruppel-like factor 4 (KLF4). The study also demonstrated significant enrichment of miR-137 at the synapses of cortical and hippocampal neurons, suggesting a role of miR-137 in regulating local synaptic protein synthesis machinery. 22003227 HMDD v2.0 hsa-miR-601 lupus vulgaris miR-601: upregulation 18998140 HMDD v2.0 hsa-miR-184 melanoma inhibit cell proliferation|inhibit cell invasion|inhibit tumor formation 21541354 OncomiRDB hsa-miR-17-5p breast cancer NPA 21765466 OncomiRDB hsa-miR-184 tongue cancer miR-184: overexpressed 19219377 HMDD v2.0 hsa-miR-133b prostate cancer inhibit cell proliferation|increase apoptosis sensitivity 22532850 OncomiRDB hsa-miR-451b pancreatic cancer The expression of let-7c, let-7f, and miR-200c were significantly reduced in most patients whereas the expression of miR-486-5p and miR-451 were significantly elevated in all pancreas cancer patients. 22929886 HMDD v2.0 hsa-miR-193a-3p colorectal cancer up 23758639 dbDEMC v2.0 hsa-miR-591 colon cancer up 24239208 dbDEMC v2.0 hsa-miR-574-5p lung cancer increase tumor progression 23133627 OncomiRDB hsa-miR-146b-5p brain cancer up 24519663 dbDEMC v2.0 hsa-miR-520b hepatocellular carcinoma MicroRNA-520b inhibits growth of hepatoma cells by targeting MEKK2 and cyclin D1. 22319632 HMDD v2.0 hsa-miR-199a-5p testicular cancer inhibit cell growth|inhibit cell migration|inhibit cell invasion|inhibit metastasis 21383689 OncomiRDB hsa-miR-498 hepatocellular carcinoma This miRNA was down-regulated in HepG2 cells treated with BJA32515. 22027761 HMDD v2.0 hsa-miR-3196 basal cell carcinoma downregulated in the tumor center 22540308 HMDD v2.0 hsa-miR-137 glioblastoma MicroRNA-137 is downregulated in glioblastoma and inhibits the stemness of glioma stem cells by targeting RTVP-1. 23714687 HMDD v2.0 hsa-miR-451a non small cell lung cancer This study showed that miRNA-451 expression decreased in non small cell lung cancer (NSCLC) tissues and that its expression was negatively associated with lymph node metastasis, the stage of TNM classification and poor prognosis of NSCLC patients. Moreover, significantly different miRNA-451 expression levels were found between smoking and non-smoking patients. The overexpression of miRNA-451 inhibited cell cycle progression, cellular migration and the invasive ability of NSCLC cells.Increased miRNA-451 expression also promoted anoikis of NSCLC cells. 21875770 HMDD v2.0 hsa-miR-429 endometrial cancer The entire miR-200 family (miR-200a/b/c, miR-141, and miR-429) was up-regulated in cases of EEC (endometrioid endometrial adenocarcinoma). 21897839 HMDD v2.0 hsa-miR-718 breast cancer The miRNA is down-regulated in whole blood of breast cancer patients 22242178 HMDD v2.0 hsa-miR-375 breast cancer Two circulating miRNAs, miR-375 and miR-122, exhibited strong correlations with clinical outcomes, including NCT response and relapse with metastatic disease.miR-122 prevalence in the circulation predicts BC metastasis in early-stage patients. 22400902 HMDD v2.0 hsa-miR-320a type 2 diabetes mellitus decreased in plasma 20651284 HMDD v2.0 hsa-miR-647 prostate cancer miR-519d,and miR-647 could be used to separate patients with and without biochemical recurrence 21703393 HMDD v2.0 hsa-miR-199a-3p hepatocellular carcinoma induce cell cycle G1 arrest|inhibit cell invasion|enhance susceptibility to hypoxia|increase doxorubicin-induced apoptosis 20501828 OncomiRDB hsa-miR-190b neuroblastoma MiR-190 leads to aggressive phenotype of neuroblastoma through indirect activation of TrkB pathway 23245204 HMDD v2.0 hsa-miR-107 breast cancer miR-107:In human breast cancer, high levels of miR-103/107 are associated with metastasis and poor outcome 20603000 HMDD v2.0 hsa-miR-483-5p mesothelioma down 23828229 dbDEMC v2.0 hsa-miR-137 cancer miR-137 restoration sensitizes multidrug-resistant MCF-7/ADM cells to anticancer agents by targeting YB-1 23178914 HMDD v2.0 hsa-miR-1248 breast cancer up 24917463 dbDEMC v2.0 hsa-miR-451a trophoblasts miR-451:a set of seven miRNAs (miR-93, miR-205, miR-224, miR-335, miR-424, miR-451, and miR-491) that are differentially regulated in primary trophoblasts 20065103 HMDD v2.0 hsa-miR-520e heart failure downregulated 17606841 HMDD v2.0 hsa-miR-125a-5p non small cell lung cancer promote cell invasion|promote cell migration 20569443 OncomiRDB hsa-miR-206 prolactinoma miR-206 was significantly up-regulated in prolactinomas following bromocriptine treatment. 22366961 HMDD v2.0 hsa-miR-107 esophageal cancer down 18172293 dbDEMC v2.0 hsa-miR-320b renal cell carcinoma Up-regulation in serum and tissue of RCC patients: miR-7-1*, miR-93, miR-106b*, miR-210, miR-320b, miR-1233 and miR-1290 21984948 HMDD v2.0 hsa-miR-206 rhabdomyosarcoma miR-206 integrates multiple components of differentiation pathways to control the transition from growth to differentiation in rhabdomyosarcoma cells. 22541669 HMDD v2.0 hsa-miR-498 rheumatoid arthritis deregulated 22100329 HMDD v2.0 hsa-miR-206 waldenstrom macroglobulinemia miR-206: increased expression 19074725 HMDD v2.0 hsa-miR-125a-3p brain cancer up 24519663 dbDEMC v2.0 hsa-miR-103b pancreatic cancer The driving miRNAs were miR-103, miR-23a and miR-15b in pancreatic cancers. 22479426 HMDD v2.0 hsa-miR-133b bladder carcinoma dysregulated 21133599 HMDD v2.0 hsa-miR-151b thyroid carcinoma The expression of serum let-7e, miR-151-5p, and miR-222 was significantly increased in PTC (papillary thyroid carcinomas ) cases relative to benign cases and healthy controls. Serum let-7e, miR-151-5p, and miR-222 levels were found to be well correlated with certain clinicopathological variables, such as nodal status, tumor size, multifocal lesion status, and Tumor-Node-Metastasis stage. 22472564 HMDD v2.0 hsa-miR-17-3p prostate cancer reduce cell motility|reduce cell invasion|inhibit tumor growth 19771525 OncomiRDB hsa-miR-206 waldenstrom macroglobulinemia miR-206:Waldenstr?m macroglobulinemia (WM) cells present with increased expression of microRNA-206 (miRNA-206) and reduced expression of miRNA-9 20519629 HMDD v2.0 hsa-miR-378i basal cell carcinoma downregulated in the tumor center 22540308 HMDD v2.0 hsa-miR-137 glioma inhibit cell proliferation|inhibit cell invasion 22406049 OncomiRDB hsa-miR-320a colon cancer inhibit cell proliferation 22459450 OncomiRDB hsa-miR-107 pituitary cancer MicroRNA miR-107 is overexpressed in pituitary adenomas and in vitro inhibits the expression of aryl hydrocarbon receptor-interacting protein (AIP). 22811466 HMDD v2.0 hsa-miR-424-5p ovarian cancer up 24512620 dbDEMC v2.0 hsa-miR-620 colon cancer up 24239208 dbDEMC v2.0 hsa-miR-133b breast cancer up 23797906 dbDEMC v2.0 hsa-miR-145-5p colon cancer down 24239208 dbDEMC v2.0 hsa-miR-520h gout There was a clear link between the rs1333049 genotypic and allelic frequencies between gout cases and controls. There was a significantly increased risk of gout in carriers of the CC genotype.This SNP is homologous to miR-519 and miR-520. 21558165 HMDD v2.0 hsa-miR-422a colorectal cancer inhibit cell cycle G1/S transition 22469014 OncomiRDB hsa-miR-1293 Kaposi's sarcoma We show a direct repression of vIL-6 by hsa-miR-1293 and hIL-6 by hsa-miR-608. The repression of vIL-6 by miR-1293 was reversed by disruption of the vIL-6 miR-1293 seed match through the introduction of point mutations. In addition, expression of vIL-6 or hIL-6 in KSHV-infected cells could be enhanced by transfection of the respective miRNA inhibitors. In situ hybridization of human lymph node sections revealed that miR-1293 is primarily expressed in the germinal centre but is deficient in the mantle zone of lymph nodes, where the expression of vIL-6 is often found in patients with KSHV-associated multicentric Castleman's disease, providing evidence of an anatomical correlation. 21984125 HMDD v2.0 hsa-miR-375 ovarian cancer Mir-375 enhances ruthenium-derived compound Rawq01 induced cell death in human ovarian cancer. 23696927 HMDD v2.0 hsa-miR-518b hepatocellular carcinoma This miRNA was down-regulated in HepG2 cells treated with BJA32515. 22027761 HMDD v2.0 hsa-miR-527 hepatocellular carcinoma This miRNA was down-regulated in HepG2 cells treated with BJA32515. 22027761 HMDD v2.0 hsa-miR-658 gastric cancer miR-658: overexpressed 19175831 HMDD v2.0 hsa-miR-885-5p pheochromocytoma up 23660872 dbDEMC v2.0 hsa-miR-409-3p gastric cancer inhibit cell proliferation|induce cell apoptosis 22388101 OncomiRDB hsa-miR-610 gastric cancer reduce cell migration|reduce cell invasion 22189055 OncomiRDB hsa-miR-140-5p hepatocellular carcinoma inhibit cell proliferation|inhibit metastasis 23401231 OncomiRDB hsa-miR-421 pancreatic cancer promote cell proliferation|promote colony formation 21352803 OncomiRDB hsa-miR-107 heart failure downregulated 17606841 HMDD v2.0 hsa-miR-375 colorectal cancer down 23028787 dbDEMC v2.0 hsa-miR-637 hypertension A common genetic variant (rs938671) in the 3'-UTR of Vacuolar H+-ATPase ATP6V0A1 creates a micro-RNA (hsa-miR-637) motif to alter Chromogranin A (CHGA) processing and hypertension risk. 21558123 HMDD v2.0 hsa-miR-137 Alzheimer's disease We identified that the loss of miR-137, -181c, -9, and 29a/b-1 increases SPT and in turn Abeta levels, and provides a mechanism for the elevated risk of AD associated with age, high-saturated-fat diet, and gender. Finally, these results suggest SPT and the respective miRNAs may be potential therapeutic targets for sporadic AD. 21994399 HMDD v2.0 hsa-miR-137 oral cancer MiR-375 is repressed and miR-127 activated in OSCC, and we confirm previous reports of miR-137 hypermethylation in oral cancer. The miR-200 s/miR-205 were epigenetically activated in tumors vs normal tissues, but repressed in the absence of DNA hypermethylation specifically in CD44(high) oral CSCs. Aberrant miR-375 and miR-200a expression and miR-200c-141 methylation could be detected in and distinguish OSCC patient oral rinse and saliva from healthy volunteers. 22132151 HMDD v2.0 hsa-miR-378e prostate cancer MiR-375, miR-378*, and miR-141 were significantly over-expressed in serum from CRPC patients compared with serum from low-risk localized patients, while miR-409-3p was significantly under-expressed. In prostate primary tumor samples, miR-375 and miR-141 also had significantly higher expression levels compared with those in normal prostate tissue. 22887127 HMDD v2.0 hsa-miR-622 rectal cancer Microarray analysis selected 14 miRNAs as being differentially expressed in TRG1 patients, and 13 were confirmed by qRT-PCR: 11 miRNAs (miR-1183, miR-483-5p, miR-622, miR-125a-3p, miR-1224-5p, miR-188-5p, miR-1471, miR-671-5p, miR-1909?, miR-630, miR-765) were significantly upregulated in TRG1 patients, 2 (miR-1274b, miR-720) were downexpressed. MiR-622 and miR-630 had a 100% sensitivity and specificity in selecting TRG1 cases. 22172905 HMDD v2.0 hsa-miR-139-5p colorectal cancer inhibit cell growth 21963845 OncomiRDB hsa-miR-137 colorectal cancer miR-124, miR-137 and miR-340 regulate colorectal cancer growth via inhibition of the Warburg effect. 22895557 HMDD v2.0 hsa-miR-320a renal cell carcinoma Up-regulated in the blook serum of patients with renal cell carcinoma compared to healthy controls. 22440013 HMDD v2.0 hsa-miR-320b interstitial cystitis demonstrate a direct correlation between miR-449b, miR-500, miR-328, and miR-320 and a down-regulation of NK1R mRNA and/or protein levels 20008142 HMDD v2.0 hsa-miR-103b endometrial cancer microRNA-103 regulates the growth and invasion of endometrial cancer cells through the downregulation of tissue inhibitor of metalloproteinase 3. 22783422 HMDD v2.0 hsa-miR-601 gastric cancer A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemoresistance 22112324 HMDD v2.0 hsa-miR-28-5p lymphoma down 21921041 dbDEMC v2.0 hsa-miR-146b-5p papillary thyroid carcinoma increase cell proliferation|inhibit TGF-¦Â signaling 21874046 OncomiRDB hsa-miR-451a cancer miR-451: miR-27a and miR-451 regulate expression of MDR1/P-glycoprotein 18619946 HMDD v2.0 hsa-miR-375 prostate cancer MiR-375, miR-378*, and miR-141 were significantly over-expressed in serum from CRPC patients compared with serum from low-risk localized patients, while miR-409-3p was significantly under-expressed. In prostate primary tumor samples, miR-375 and miR-141 also had significantly higher expression levels compared with those in normal prostate tissue. 22887127 HMDD v2.0 hsa-miR-429 colon cancer up 24239208 dbDEMC v2.0 hsa-miR-375 hepatocellular carcinoma MicroRNA-375 targets AEG-1 in hepatocellular carcinoma and suppresses liver cancer cell growth in vitro and in vivo. 22056881 HMDD v2.0 hsa-miR-133b bladder carcinoma deregulated 22140553 HMDD v2.0 hsa-miR-1258 breast cancer Suppresses Breast Cancer Brain Metastasis by Targeting Heparanase. 21266359 HMDD v2.0 hsa-miR-1302 adenoviridae infections miR-1302-1:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control 20634878 HMDD v2.0 hsa-miR-217 pancreatic cancer miR-217: biomarkers improved the ability to distinguish between healthy tissue, PDAC, and chronic pancreatitis 18719196 HMDD v2.0 hsa-miR-421 adenoviridae infections miR-421:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control 20634878 HMDD v2.0 hsa-miR-409-3p gastric cancer reduce cell migration|reduce cell invasion|reduce distal pulmonary metastases|reduce peritoneal dissemination 22179828 OncomiRDB hsa-miR-30e-3p colorectal cancer inhibit cell growth 21963845 OncomiRDB hsa-miR-1972 adenoviridae infections miR-1972:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control 20634878 HMDD v2.0 hsa-miR-592 eosinophilic esophagitis upregulated 22391115 HMDD v2.0 hsa-miR-492 psoriasis The rs8259 T allele was associated with significantly decreased psoriasis susceptibility (OR?=?0.758, 95% CI 0.638-0.901, p?=?0.002) compared to A allele. the rs8259 polymorphism was located in a seed region for miR-492 binding. 21655935 HMDD v2.0 hsa-miR-184 prostate cancer down 19676045 dbDEMC v2.0 hsa-miR-326 breast cancer Involvement of miR-326 in chemotherapy resistance of breast cancer through modulating expression of multidrug resistance-associated protein 1 19883630 HMDD v2.0 hsa-miR-133b myocardial infarction dysregulation 20075508 HMDD v2.0 hsa-miR-199b-5p medulloblastoma NPA 22411914 OncomiRDB hsa-miR-663a lupus vulgaris miR-663: downregulation 18998140 HMDD v2.0 hsa-miR-608 hepatocellular carcinoma hsa-miR-608 was down-regulated in HepG2 cells after 5 hours of culture with epigallocatechin gallate. 21998738 HMDD v2.0 hsa-miR-1303 colorectal cancer hsa-miR-1273c, hsa-miR-1303 and hsa-miR-567, with frequent and sometimes bi-allelic mutations in MSI tumors. 22348132 HMDD v2.0 hsa-miR-484 adrenocortical carcinoma miR-484: down-regulated 19351815 HMDD v2.0 hsa-miR-378b renal cell carcinoma The level of miR-378 was significantly increased in serum of ccRCC patients. 22542158 HMDD v2.0 hsa-miR-595 gastric cancer A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemoresistance 22112324 HMDD v2.0 hsa-miR-378e bladder carcinoma hsa-miR-29c, hsa-miR-200a, hsa-miR-378, hsa-miR-429, hsa-miR-200c and hsa-miR-141 were up-regulated, while hsa-miR-451 was down-regulated. 22886973 HMDD v2.0 hsa-miR-637 hypertension ATP6V0A1 Polymorphism and MicroRNA-637 may have A Pathogenetic Role for MicroRNAs in Essential Hypertension. 21846868 HMDD v2.0 hsa-miR-574-3p bladder carcinoma inhibit cell proliferation|inhibit cell migration|inhibit cell invasion|induce apoptosis 22179486 OncomiRDB hsa-miR-572 multiple sclerosis Six plasma miRNA (miR-614, miR-572, miR-648, miR-1826, miR-422a and miR-22) that were significantly up-regulated and one plasma miRNA (miR-1979) that was significantly down-regulated in MS individuals. 22231906 HMDD v2.0 hsa-miR-375 adrenocortical carcinoma down 20484036 dbDEMC v2.0 hsa-miR-17-5p melanoma up 20304954 dbDEMC v2.0 hsa-miR-630 rectal cancer Microarray analysis selected 14 miRNAs as being differentially expressed in TRG1 patients, and 13 were confirmed by qRT-PCR: 11 miRNAs (miR-1183, miR-483-5p, miR-622, miR-125a-3p, miR-1224-5p, miR-188-5p, miR-1471, miR-671-5p, miR-1909?, miR-630, miR-765) were significantly upregulated in TRG1 patients, 2 (miR-1274b, miR-720) were downexpressed. MiR-622 and miR-630 had a 100% sensitivity and specificity in selecting TRG1 cases. 22172905 HMDD v2.0 hsa-miR-375 small cell lung cancer NPA 22172490 OncomiRDB hsa-miR-375 pancreatic cancer The miRNA is Potentially Associated with Antiproliferative Activity of Benzyl Isothiocyanate in Pancreatic Cancer 21779484 HMDD v2.0 hsa-miR-375 lung cancer miR-375 is a novel prognostic indicator in NSCLC and might be a potential target for diagnosis and gene therapy 23206448 HMDD v2.0 hsa-miR-646 melanoma miR-646:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients 20529253 HMDD v2.0 hsa-miR-206 rhabdomyosarcoma inhibit cell growth|inhibit cell migration 19710019 OncomiRDB hsa-miR-421 pulmonary tuberculosis hsa-miR-421: differently expressed in the samples from study participants with active tuberculosis (TB) versus latent tuberculosis infection (LTBI). 22003408 HMDD v2.0 hsa-miR-137 gastric cancer induce apoptosis|induce cell cycle G1 arrest 21221794 OncomiRDB hsa-miR-451a non small cell lung cancer Upregulation of microRNA-451 increases cisplatin sensitivity of non small cell lung cancer cell line (A549). 21329503 HMDD v2.0 hsa-miR-564 gastric cancer up 25167801 dbDEMC v2.0 hsa-miR-217 hiv MiR-217 is involved in Tat-induced HIV-1 long terminal repeat (LTR) transactivation by down-regulation of SIRT1. 22406815 HMDD v2.0 hsa-miR-375 diabetes mellitus mir-375 was found to modulate glucose-stimulated insulin secretion and exocytosis. 16195701 HMDD v2.0 hsa-miR-151b prostate cancer Genistein Suppresses Prostate Cancer Growth through Inhibition of Oncogenic MicroRNA-151. 22928040 HMDD v2.0 hsa-miR-103b pre-eclampsia Seven microRNAs, namely miR-24, miR-26a, miR-103, miR-130b, miR-181a, miR-342-3p, and miR-574-5p, were validated to be elevated in plasma from severe pre-eclamptic pregnancies by using real-time quantitative stem-loop reverse-transcription polymerase chain reaction analysis. 22187671 HMDD v2.0 hsa-miR-1303 hepatocellular carcinoma miR-96, miR-129-1-3p, miR-1271, miR-1291 and miR-1303 differentially control GPC3 expression in HCC cells. 22865282 HMDD v2.0 hsa-miR-1290 colon cancer postpone cytokinesis|cell reprogramming 23142292 OncomiRDB hsa-miR-206 laryngeal squamous cell carcinoma inhibit cell proliferation|inhibit cell migration|inhibit cell invasion|inhibit tumorigenesis|induce apoptosis 22110210 OncomiRDB hsa-miR-331-5p leukemia increase doxorubicin sensitivity 21070600 OncomiRDB hsa-miR-429 colorectal cancer inhibit apoptosis 23111103 OncomiRDB hsa-miR-571 frontotemporal lobar degeneration miR-571 was significantly dysregulated in frontal cortex and cerebellar tissue samples of PGRN mutation carriers. 22032330 HMDD v2.0 hsa-miR-449a lung cancer inhibit cell growth 22078727 OncomiRDB hsa-miR-206 ERalpha-positive breast cancer inhibit cell growth 18593897 OncomiRDB hsa-miR-569 systemic lupus erythematosus Association of a functional polymorphism in the 3' untranslated region of SPI1 with systemic lupus erythematosus. 21162035 HMDD v2.0 hsa-miR-592 colon cancer down 19922656 dbDEMC v2.0 hsa-miR-337-3p colorectal cancer increase reactive oxygen species (ROS) production|increase cell senescence 23137536 OncomiRDB hsa-miR-498 ovarian cancer inhibit tumor growth 23055531 OncomiRDB hsa-miR-198 lupus vulgaris miR-198: upregulation 18998140 HMDD v2.0 hsa-miR-205-5p ovarian cancer down 24512620 dbDEMC v2.0 hsa-miR-331-3p agressive prostate cancer inhibit cell growth|induce apoptosis 19996289 OncomiRDB hsa-miR-320a ovarian cancer copy number loss 16754881 HMDD v2.0 hsa-miR-1273c colorectal cancer hsa-miR-1273c, hsa-miR-1303 and hsa-miR-567, with frequent and sometimes bi-allelic mutations in MSI tumors. 22348132 HMDD v2.0 hsa-miR-429 melanoma copy number gain 16754881 HMDD v2.0 hsa-miR-137 colorectal cancer inhibit cell proliferation|induce G1 cell cycle arrest|inhibit cell invasion 20473940 OncomiRDB hsa-miR-375 eosinophilic esophagitis The most downregulated miRNA, which strongly correlated with esophageal eosinophil levels. 22391115 HMDD v2.0 hsa-miR-338-5p gastric cancer down 25167801 dbDEMC v2.0 hsa-miR-99b-3p gastric cancer up 25167801 dbDEMC v2.0 hsa-miR-423-5p lung cancer down 23029380 dbDEMC v2.0 hsa-miR-491-5p glioblastoma multiforme inhibit cell invasion 21831363 OncomiRDB hsa-miR-17-5p cervical cancer inhibit cell growth|promote apoptosis 22730212 OncomiRDB hsa-miR-137 glioblastoma miR-181b, miR-153, miR-145, miR-137, and let-7d were significantly upregulated after treatment with both TMZ (temozolomide ) and OLE (Olea europaea leaf extract). 22722712 HMDD v2.0 hsa-miR-133b sarcoma down 23133552 dbDEMC v2.0 hsa-miR-34c-5p breast cancer up 21364938 dbDEMC v2.0 hsa-miR-429 gastric cancer miRNA-429 may serve as a tumor suppressor during tumorigenesis of gastric cancer and may be a potential gastric cancer therapeutic target 23554776 HMDD v2.0 hsa-miR-429 ehrlich tumor carcinoma Two clusters miR-183~miR-96~miR-182 and miR-200b~miR-200a~miR-429 as well as miR-141 to be consistently up-regulated in the MDR (Multidrug resistance) cell lines, while miR-125b-5p and the two clusters miR-30d~miR-30b and miR-23b~miR-27b~miR-24-1 were down-regulated in most of the resistant EAT (Ehrlich ascites tumor) cells. 21899346 HMDD v2.0 hsa-miR-661 gastric cancer A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemoresistance 22112324 HMDD v2.0 hsa-miR-429 bladder carcinoma hsa-miR-29c, hsa-miR-200a, hsa-miR-378, hsa-miR-429, hsa-miR-200c and hsa-miR-141 were up-regulated, while hsa-miR-451 was down-regulated. 22886973 HMDD v2.0 hsa-miR-429 breast cancer The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. 18376396 HMDD v2.0 hsa-miR-596 oral cancer Potential of tumor-suppressive miR-596 targeting LGALS3BP as a therapeutic agent in oral cancer 23233740 HMDD v2.0 hsa-miR-133b gastric cancer Five microRNAs (miR-125a-3p, miR-133b, miR-143, miR-195 and miR-212) were differently expressed between different metastatic groups in 30 gastric cancer biopsies (P < 0.05). Partial correlation analysis showed that hsa-miR-212 and hsa-miR-195 were correlated with the status of metastasis to LN in spite of age, gender, tumor location, tumor size, depth of invasion and cell differentiation. ROC analysis indicated that miR-212 and miR-195 have better sensitivities (84.6% and 69.2%, respectively) and specificities (both 100%) in distinguishing biopsies with metastasis to LN from biopsies without metastasis to LN. 21987613 HMDD v2.0 hsa-miR-421 gastric cancer A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemosensitivity 22112324 HMDD v2.0 hsa-miR-429 endometrial endometrioid carcinoma promote cell growth 21035172 OncomiRDB hsa-miR-1181 hepatitis c miR-24, miR-149, miR-638 and miR-1181 were identified to be involved in HCV entry, replication and propagation 20006370 HMDD v2.0 hsa-miR-297 heart failure upregulated 17606841 HMDD v2.0 hsa-miR-133b lung cancer serum;Alteration of serum miR-206 and miR-133b is associated with lung carcinogenesis induced by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone 23337359 HMDD v2.0 hsa-miR-632 breast cancer promote cell invasion 22710984 OncomiRDB hsa-miR-195-5p bladder carcinoma decrease cell glucose uptake|inhibit cell growth|promote apoptosis 22265971 OncomiRDB hsa-miR-602 lupus vulgaris miR-602: downregulation 18998140 HMDD v2.0 hsa-miR-1246 adenoviridae infections miR-1246:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control 20634878 HMDD v2.0 hsa-miR-302e gastric cancer Real-time RT-PCR analysis demonstrated an increase in mir-21 and mir-302 expression level in CSCs(cancer stem cells), relative to cancer cells, whereas let-7a expression level was decreased in CSC in comparison with cancer cells. mir-372, mir-373 and mir-520c-5p were markedly increased in cancer cells in comparison with CSCs. 22374783 HMDD v2.0 hsa-miR-21-5p colon cancer up 24239208 dbDEMC v2.0 hsa-miR-151b breast cancer miR-151-5p upregulation may suppress metastasis in primary breast tumors. 22489664 HMDD v2.0 hsa-miR-375 colorectal cancer miR-375 expression was frequently downregulated in the colorectal cancer tissues compared to the non-tumor counterparts 22377847 HMDD v2.0 hsa-miR-513a-3p non small cell lung cancer increase cisplatin sensitivity 22749944 OncomiRDB hsa-miR-137 glioblastoma multiforme induce cell cycle arrest 18577219 OncomiRDB hsa-miR-320b breast cancer Expression of the Pten-miR-320-Ets2-regulated secretome distinguished human normal breast stroma from tumour stroma and robustly correlated with recurrence in breast cancer patients. This work reveals miR-320 as a critical component of the Pten tumour-suppressor axis that acts in stromal fibroblasts to reprogramme the tumour microenvironment and curtail tumour progression. 22179046 HMDD v2.0 hsa-miR-429 adenocarcinoma miR-429: upregulated 19077565 HMDD v2.0 hsa-miR-498 Kaposi's sarcoma Cellular MicroRNAs 498 and 320d Regulate Herpes Simplex Virus 1 Induction of Kaposi's Sarcoma-Associated Herpesvirus Lytic Replication by Targeting RTA 23418466 HMDD v2.0 hsa-miR-137 colorectal cancer deregulated 21694772 HMDD v2.0 hsa-miR-449a salivary gland neoplasms miR-449: up-regulated 19347935 HMDD v2.0 hsa-miR-17-5p renal cell carcinoma NPA 22326755 OncomiRDB hsa-miR-320d Kaposi's sarcoma Cellular MicroRNAs 498 and 320d Regulate Herpes Simplex Virus 1 Induction of Kaposi's Sarcoma-Associated Herpesvirus Lytic Replication by Targeting RTA 23418466 HMDD v2.0 hsa-miR-1256 prostate cancer Epigenetic deregulation of miR-29a and miR-1256 by isoflavone contributes to the inhibition of prostate cancer cell growth and invasion. 22805767 HMDD v2.0 hsa-miR-133b osteosarcoma miRNA expression profile in human osteosarcoma: Role of miR-1 and miR-133b in proliferation and cell cycle control 23229283 HMDD v2.0 hsa-miR-320c breast cancer Expression of the Pten-miR-320-Ets2-regulated secretome distinguished human normal breast stroma from tumour stroma and robustly correlated with recurrence in breast cancer patients. This work reveals miR-320 as a critical component of the Pten tumour-suppressor axis that acts in stromal fibroblasts to reprogramme the tumour microenvironment and curtail tumour progression. 22179046 HMDD v2.0 hsa-miR-151b nasopharyngeal cancer A miR-151 binding site polymorphism in the 3'-untranslated region of the cyclin E1 gene associated with nasopharyngeal carcinoma 23416081 HMDD v2.0 hsa-miR-331-3p prostate cancer inhibit AR signaling|inhibit PI3K/AKT signaling 19584056 OncomiRDB hsa-miR-182-5p prostate cancer promote cell proliferation|promote cell migration|promote cell invasion 23383207 OncomiRDB hsa-miR-206 breast cancer reduce cell proliferation|induce apoptosis 19423651 OncomiRDB hsa-miR-574-3p breast cancer up 24917463 dbDEMC v2.0 hsa-miR-650 chronic lymphocytic leukemia influence cell proliferation 22234685 OncomiRDB hsa-miR-485-3p hepatocellular carcinoma promote tumor growth|promote cell invasion|promote metastasis 23241961 OncomiRDB hsa-miR-615-3p esophageal cancer down 21128279 dbDEMC v2.0 hsa-miR-320a colon cancer down 24239208 dbDEMC v2.0 hsa-miR-582-5p NPA NPA 22306127 OncomiRDB hsa-miR-378g renal cell carcinoma The level of miR-378 was significantly increased in serum of ccRCC patients. 22542158 HMDD v2.0 hsa-miR-206 renal cell carcinoma miR-210, miR-184 and miR-206) play pivotal roles in ccRCC development 21253009 HMDD v2.0 hsa-miR-575 leukemia miR-575: downregulated during human leukemic HL-60 cell differentiation induced by 4-hydroxynonenal 19022373 HMDD v2.0 hsa-miR-107 head and neck cancer Lipid-based Nanoparticle Delivery of Pre-miR-107 Inhibits the Tumorigenicity of Head and Neck Squamous Cell Carcinoma. 22491216 HMDD v2.0 hsa-miR-137 NPA inhibit cell proliferation 21881409 OncomiRDB hsa-miR-107 type 2 diabetes mellitus over-expressed in insulin target tissues 19689793 HMDD v2.0 hsa-miR-1322 esophageal squamous cell carcinoma NPA 22315007 OncomiRDB hsa-miR-107 breast cancer The miRNA is down-regulated in whole blood of breast cancer patients 22242178 HMDD v2.0 hsa-miR-133b parkinson disease Expression of one of these precursor miRNAs, miR-133b, was specifically enriched in the midbrain and deficient in the context of Parkinson's disease patient samples, as determined by ribonuclease (RNase) protection assays, qPCR, and Northern blotting for mature miR-133b. 17761882 HMDD v2.0 hsa-miR-451a non small cell lung cancer MicroRNA-451 functions as a tumor suppressor in human non small cell lung cancer by targeting ras-related protein 14 (RAB14). 21358675 HMDD v2.0 hsa-miR-137 squamous cell carcinoma MicroRNA-137 promoter methylation is associated with poorer overall survival in patients with squamous cell carcinoma of the head and neck. 21425146 HMDD v2.0 hsa-miR-7515 lung cancer decrease cell proliferation|decrease cell migration|decrease cell invasion 23087254 OncomiRDB hsa-miR-320a diabetes mellitus miR-320 Regulates Glucose-Induced Gene Expression in Diabetes. 22900199 HMDD v2.0 hsa-miR-20b-5p colon cancer up 24239208 dbDEMC v2.0 hsa-miR-142-5p lymphoma down 24121164 dbDEMC v2.0 hsa-miR-409-3p fibrosarcoma inhibit cell proliferation|inhibit angiogenesis|inhibit metastasis 22531314 OncomiRDB hsa-miR-92a-3p colon cancer up 24239208 dbDEMC v2.0 hsa-miR-520b non small cell lung cancer The authors found a number of miRNAs (miR-17, miR-135, miR-520, miR-124-1, and miR-34c) that may rescue cell viability from caspase-8 activation. 22370637 HMDD v2.0 hsa-miR-107 Alzheimer's disease downregulated 18234899 HMDD v2.0 hsa-miR-326 glioma Pyruvate kinase M2 is a target of the tumor-suppressive microRNA-326 and regulates the survival of glioma cells 20667897 HMDD v2.0 hsa-miR-638 lung cancer We found the upregulation of microRNA-638 and microRNA-923 in bostrycin-treated lung adenocarcinoma cells 21303527 HMDD v2.0 hsa-miR-107 head and neck cancer microRNA-107 functions as a candidate tumor-suppressor gene in head and neck squamous cell carcinoma by downregulation of protein kinase C? 22158047 HMDD v2.0 hsa-miR-451a glioma MicroRNA-451 regulates LKB1/AMPK signaling and allows adaptation to metabolic stress in glioma cells 20227367 HMDD v2.0 hsa-miR-520h squamous cell carcinoma Thirteen miRNA were significantly overexpressed (miR-489, miR-129, miR-23a, miR-214, miR-23b, miR-92, miR-25, miR-210, miR-212, miR-515, miR-146b, miR-21, miR-338) and 6 miRNA were underexpressed (miR-520h, miR-197, miR-378, miR-135b, miR-224, miR-34a) in oral tumours. Underexpression of mir-155, let-7i, mir-146a was found to characterize progression to metastastatic tumours. 21244772 HMDD v2.0 hsa-miR-199a-3p breast cancer promote cell proliferation|promote cell survival 21807947 OncomiRDB hsa-miR-133b acute coronary syndrome miR-1, miR-133a, miR-133b, and miR-208b were independently associated with hsTnT levels (all P<0.001). Patients with myocardial infarction presented with higher levels of miR-1, miR-133a, and miR-208b compared with patients with unstable angina. 21806992 HMDD v2.0 hsa-miR-362-3p colorectal cancer reduce cell viability|inhibit cell proliferation|cell cycle 23280316 OncomiRDB hsa-miR-200b-3p androgen-independent prostate cancer inhibit cell proliferation 23389960 OncomiRDB hsa-miR-206 Duchenne muscular dystrophy the serum levels of several muscle-specific miRNAs (miR-1, miR-133a and miR-206) are increased 21479190 HMDD v2.0 hsa-miR-641 hpv infection We found hypermethylation of miR-432, miR-1286, miR-641, miR-1290, miR-1287 and miR-95 may have some relationship with HPV infection in cervical cell lines. 23732000 HMDD v2.0 hsa-miR-451a colorectal cancer Microrna-451 is Involved in the Self-Renewal, Tumorigenicity and Chemoresistance of Colorectal Cancer Stem Cells. 21948564 HMDD v2.0 hsa-miR-202-3p ovarian cancer up 24512620 dbDEMC v2.0 hsa-miR-375 breast cancer CTC (circulating tumour cells)-positive had significantly higher levels of miR-141, miR-200a, miR-200b, miR-200c, miR-203, miR-210, miR-375 and miR-801 than CTC-negative MBC and controls (P < 0.00001), while miR-768-3p was present in lower amounts in MBC (metastatic breast cancer) cases (P < 0.05). 22952344 HMDD v2.0 hsa-miR-217 pancreatic ductal adenocarcinoma inhibit cell growth|inhibit anchorage-independent colony formation|decrease tumor growth 20675343 OncomiRDB hsa-miR-133b Duchenne muscular dystrophy miR-1, miR-133, and miR-206 are new and valuable biomarkers for the diagnosis of DMD and possibly also for monitoring the outcomes of therapeutic interventions in humans 21425469 HMDD v2.0 hsa-miR-375 salivary gland neoplasms miR-375: down-regulated 19347935 HMDD v2.0 hsa-miR-518b esophageal cancer hsa-miR-126 is upregulated and hsa-miR-518b is downregulated in esophageal squamous cell carcinoma 21269950 HMDD v2.0 hsa-miR-103a-3p colon cancer up 24239208 dbDEMC v2.0 hsa-miR-922 breast cancer The miRNA is up-regulated in whole blood of breast cancer patients 22242178 HMDD v2.0 hsa-miR-206 amyotrophic lateral sclerosis MicroRNA-206 delays ALS progression and promotes regeneration of neuromuscular synapses in mice 20007902 HMDD v2.0 hsa-miR-1286 esophageal cancer Thirteen miRNAs (miR-199a-5p, miR-302f, miR-320a, miR-342-3p, miR-425, miR-455-3p, miR-486-3p, miR-519c-5p, miR-548d-5p, miR-617, miR-758, miR-766, miR-1286) were deregulated after 24- and/or 72-h treatment by Chemotherapy. 21743970 HMDD v2.0 hsa-miR-378c prostate cancer MiR-375, miR-378*, and miR-141 were significantly over-expressed in serum from CRPC patients compared with serum from low-risk localized patients, while miR-409-3p was significantly under-expressed. In prostate primary tumor samples, miR-375 and miR-141 also had significantly higher expression levels compared with those in normal prostate tissue. 22887127 HMDD v2.0 hsa-miR-375 esophageal cancer Circulating miR-21 and miR-375 could be reliable prognostic markers for ESCC. 22519435 HMDD v2.0 hsa-miR-422a atherosclerosis Co-expression in plaque tissue and non-classical monocytes. 22370758 HMDD v2.0 hsa-miR-1184 adenoviridae infections miR-1184:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control 20634878 HMDD v2.0 hsa-miR-630 colon cancer miR-630:In particular, miR-126, miR-142-3p, miR-155, miR-552, and miR-630 were all upregulated, whereas miR-146a, miR-152, miR-205, miR-365, miR-449, miR-518c, miR-584, miR-615, and miR-622 were downregulated after NGX6 transfection. 20859756 HMDD v2.0 hsa-miR-375 esophageal squamous cell carcinoma NPA 21533613 OncomiRDB hsa-miR-320c interstitial cystitis demonstrate a direct correlation between miR-449b, miR-500, miR-328, and miR-320 and a down-regulation of NK1R mRNA and/or protein levels 20008142 HMDD v2.0 hsa-miR-602 hepatocellular carcinoma MicroRNA-602 regulating tumor suppressive gene RASSF1A is overexpressed in hepatitis B virus-infected liver and hepatocellular carcinoma 20364114 HMDD v2.0 hsa-miR-199a-5p hepatocellular carcinoma inhibit cell invasion 20799954 OncomiRDB hsa-miR-302f esophageal cancer Thirteen miRNAs (miR-199a-5p, miR-302f, miR-320a, miR-342-3p, miR-425, miR-455-3p, miR-486-3p, miR-519c-5p, miR-548d-5p, miR-617, miR-758, miR-766, miR-1286) were deregulated after 24- and/or 72-h treatment by Chemotherapy. 21743970 HMDD v2.0 hsa-miR-451a hepatocellular carcinoma miR-451 Inhibits Cell Proliferation in Human Hepatocellular Carcinoma through Direct Suppression of IKK-beta 23740840 HMDD v2.0 hsa-miR-375 colorectal cancer decrease cell viability|inhibit cell cycle G1/S transition 22469014 OncomiRDB hsa-miR-325 pre-eclampsia The expression of hsa-miR-325 was downregulated in the case of PE. Changes in hsa-miR?325 expression in the case of pregnancy-related hypertensive disorders might affect the oxidative stress pathways and heat-shock protein production. 22710575 HMDD v2.0 hsa-miR-198 brain cancer up 24519663 dbDEMC v2.0 hsa-miR-611 lupus vulgaris miR-611: downregulation 18998140 HMDD v2.0 hsa-miR-107 head and neck squamous cell carcinoma inhibit cell proliferation|inhibit DNA replication|inhibit colony formation|inhibit cell invasion 22158047 OncomiRDB hsa-miR-17-5p clear cell renal cell carcinoma increase cell proliferation 20022054 OncomiRDB hsa-miR-375 laryngeal cancer Expression of mir-21 and mir-375 in laryngeal squamous cell carcinoma 23259291 HMDD v2.0